愛齊科技 (ALGN) 2011 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Welcome to the Align Technology Q4 2011 earnings call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded. Is now my pleasure to introduce Shirley Stacy of Align Technology. Ms Stacy you may begin.

    歡迎參加 Align Technology 2011 年第四季財報電話會議。此刻所有與會者皆為只聽模式。正式簡報結束後將進行簡短的問答時段。(接線員指示) 提醒各位,本次會議將被錄音。現在很榮幸為各位介紹 Align Technology 的 Shirley Stacy。Stacy 女士,您可以開始了。

  • - Senior Director - Corporate, Investor Communications

    - Senior Director - Corporate, Investor Communications

  • Good afternoon everyone. Thank you for joining us. I'm Shirley Stacy, Senior Director of Corporate and Investor Communications. Joining me today is - Tom Prescott, President and CEO; and Ken Arola, Vice President and CFO.

    各位下午好。感謝各位加入我們。我是 Shirley Stacy,企業與投資人溝通資深總監。今天與我一同出席的有——總裁暨執行長 Tom Prescott,以及副總裁暨財務長 Ken Arola。

  • Before we begin, let me cover some housekeeping items. We issued our fourth quarter and fiscal year-end 2011 financial results press release today via Globe Newswire, which is available on our website at Investor.AlignTech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months.

    在開始之前,我先說明幾項會議事項。我們今天透過 Globe Newswire 發布了 2011 年第四季及會計年度年終財務結果新聞稿,可於我們網站 Investor.AlignTech.com 取得。今天的電話會議將以音訊網路直播,並會在我們網站上存檔約 12 個月。

  • A telephone replay will be available today by approximately 5.30 PM Eastern time through 5.30 PM Eastern time on February 6, 2012. To access the replay domestic callers should dial 877-660-6853 with account number 292 followed by pound and conference number 386750 followed by pound. International callers should dial 201-612-7415 with the same account number and conference number.

    電話重播將於今日美東時間約下午 5 點 30 分提供,並持續至 2012 年 2 月 6 日美東時間下午 5 點 30 分。美國境內來電者請撥 877-660-6853,輸入帳戶號碼 292 後按井字鍵,再輸入會議號碼 386750 後按井字鍵。國際來電者請撥 201-612-7415,並使用相同的帳戶號碼與會議號碼。

  • As a reminder, the information that the presenters discuss today will include forward-looking statements, including, without limitation, statements about Align's future events, product outlook and the expected financial results for the first quarter of fiscal 2011. These forward-looking statements are only predictions and involve risks and uncertainties such that actual results may vary significantly. These and other risks are set forth in more detail in our Form 10-Q for the fiscal quarter ended September 30, 2011.

    提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括但不限於關於 Align 未來事件、產品展望,以及 2011 會計年度第一季預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性,因此實際結果可能有重大差異。這些及其他風險已在我們截至 2011 年 9 月 30 日止會計季度的 Form 10-Q 中更詳細說明。

  • These forward-looking statements reflect beliefs, estimates and predictions as of today, and Align expressly assumes no obligation to update any such forward-looking statements. Please also note that on this conference call, we will provide listeners with several financial metrics determined on a non-GAAP basis for comparisons to previous quarters. Most of these items together with the corresponding GAAP numbers and the reconciliations to the comparable GAAP financial measures, where practical, are contained in today's financial results press release which we have posted on our website at Investor.AlignTech.com under Financial Release.

    這些前瞻性陳述反映截至今日的信念、估計與預測,Align 明確表示不承擔更新任何此類前瞻性陳述的義務。另請注意,在本次電話會議中,我們將向聽眾提供若干以非 GAAP 基礎計算的財務指標,以便與前幾季比較。其中多數項目連同相對應的 GAAP 數字,以及在可行情況下與可比較 GAAP 財務衡量指標的調節表,均載於今日的財務結果新聞稿中;該新聞稿已張貼於我們網站 Investor.AlignTech.com 的 Financial Release 項下。

  • And have been furnish to the SEC on Form 8-K. We encourage listeners to review these items. We've also posted a set of GAAP and non-GAAP historical financial statements including the corresponding reconciliation and our fourth quarter conference call slides our website, under Quarterly Results. Please refer to these files for more detailed information.

    並已以 Form 8-K 形式提交給美國證券交易委員會(SEC)。我們鼓勵聽眾查閱這些項目。我們也已在網站的 Quarterly Results 項下張貼一套 GAAP 與非 GAAP 歷史財務報表(含相對應調節表),以及我們第四季電話會議投影片。請參閱這些檔案以取得更詳細資訊。

  • With that, I would like to turn the call over to Align Technology's President and CEO, Tom Prescott. Tom?

    接下來,我想把電話交給 Align Technology 總裁暨執行長 Tom Prescott。Tom?

  • - President, CEO

    - President, CEO

  • Thanks, Shirley. Good afternoon everyone. On the call today, I'll briefly recap Q4 highlights, review our performance by product and customer channel, and update you on our strategic growth initiatives, including the activity and investments surrounding our scanners and CAD/CAM services business. Ken will discuss our Q4 financial results and outlook for Q1 in more detail and provide some qualitative commentary on how we view 2012. I'll come back and summarize a few key points and open the call up to questions.

    謝謝你,Shirley。各位下午好。在今天的電話會議中,我將簡要回顧第四季重點、按產品與客戶通路檢視我們的表現,並向各位更新我們的策略性成長計畫,包括圍繞掃描器與 CAD/CAM 服務業務的活動與投資。Ken 將更詳細說明第四季財務結果與第一季展望,並就我們如何看待 2012 年提供一些質性評論。我之後會回來總結幾個重點,並開放提問。

  • The fourth quarter was a strong finish to the year for Align, and we're pleased to have delivered better than expected revenue and earnings, driven by increased Invisalign case volume and lower than projected operating expenses. We continue to see solid performance of Invisalign across all customer channels, and believe that our continuing focus on Invisalign product evolution and market expansion is at the core of this progress.

    第四季為 Align 這一年畫下強勁句點;我們很高興在 Invisalign 病例量增加以及營運費用低於預期的帶動下,交出優於預期的營收與獲利。我們持續看到 Invisalign 在所有客戶通路皆有穩健表現,並相信我們持續聚焦於 Invisalign 產品演進與市場擴張,是這項進展的核心。

  • I'll start with an overview of key highlights for Invisalign where our record Q4 Invisalign case volume of 82,600 cases increased 4.1% sequentially and 30.1% year-over-year. Like I said earlier, a strong finish to a good year.

    我先從 Invisalign 的幾項關鍵亮點概述開始:我們第四季 Invisalign 病例量創新高,達 82,600 例,較前一季增加 4.1%,較去年同期增加 30.1%。如我先前所說,為表現良好的一年帶來強勁收尾。

  • For North American GP dentists, Q4 case volume increased 6.4% from Q3 and 31% year-over-year to a record 33,100. During the quarter, we saw solid growth of Invisalign across our GP customer base, particularly with Invisalign Full and Assist.

    就北美一般牙醫(GP)而言,第四季病例量較第三季增加 6.4%,較去年同期增加 31%,創下 33,100 例的新高。本季我們看到 Invisalign 在 GP 客戶群中穩健成長,尤其是 Invisalign Full 與 Assist。

  • Results from a recent customer survey which included 300 GP practices shows that GPs attributed increased use of Invisalign to better marketing of their practices, increased clinical confidence with Invisalign and increased patient demand overall. The survey also found that overall satisfaction with Invisalign has increased among GP dentists over the past year, particularly among newly certified doctors.

    近期一項涵蓋 300 家 GP 診所的客戶調查結果顯示,GP 將 Invisalign 使用量增加歸因於:診所行銷更到位、對 Invisalign 的臨床信心提升,以及整體病患需求增加。該調查亦發現,過去一年 GP 牙醫對 Invisalign 的整體滿意度有所提升,尤其是在新近取得認證的醫師之中。

  • We believe this is due in part to the improved Invisalign doctor's site and ClinCheck's software user interface launch with Invisalign G3 that has proven to be far more intuitive and easier to use. North American Ortho case volume for Q4 was 29,890 cases, a slight decrease of a few hundred cases from Q3 as expected due to normal seasonality in Orthodontic case starts.

    我們認為,這部分原因在於 Invisalign G3 推出時同步上線的改良版 Invisalign 醫師網站與 ClinCheck 軟體使用者介面,已被證明更直覺且更容易使用。北美矯正(Ortho)第四季病例量為 29,890 例,較第三季如預期小幅減少數百例,主要因矯正病例啟動具有正常季節性。

  • Recall that more teenagers begin treatment in the summer than in the fall, and our North American Ortho starts are typically down somewhat in Q4. On a year-over-year basis Q4 Ortho case volume increased 36.3% reflecting increased penetration of Invisalign across our Ortho customer base from all products.

    請回想,青少年在夏季開始治療的人數多於秋季,而我們北美矯正的啟動量通常在第四季會略為下降。以年對年來看,第四季矯正病例量增加 36.3%,反映 Invisalign 在矯正客戶群中、涵蓋所有產品的滲透率提升。

  • Since the launch of Invisalign G3 in October of 2010, we have continued to see strong growth among Ortho customers. The customer survey I just referenced also included 200 Orthos, who attributed increased use of Invisalign to a number of factors, starting with higher patient demand created by our consumer advertising, along with clinical improvements that have resulted in improved predictability, delivered better outcomes and given them increased confidence with Invisalign.

    自 2010 年 10 月推出 Invisalign G3 以來,我們持續看到矯正客戶的強勁成長。我剛提到的客戶調查也包含 200 位矯正醫師;他們將 Invisalign 使用量增加歸因於多項因素,首先是我們面向消費者的廣告帶動病患需求提升,其次是臨床改良帶來更佳的可預測性、交付更好的治療結果,並使他們對 Invisalign 更有信心。

  • This input is consistent with other feedback regarding Invisalign G3 that we've heard from customers all year. We believe the additional new features and innovations launched in Invisalign G4 will continue to build on the progress we've seen to date with Invisalign G3 and help doctors gain greater confidence and achieve even better clinical results when treating more complex cases.

    這些意見與我們全年從客戶那裡聽到的、關於 Invisalign G3 的其他回饋一致。我們相信,Invisalign G4 所推出的更多新功能與創新,將在我們迄今於 Invisalign G3 所見進展的基礎上持續推進,並協助醫師在治療更複雜病例時建立更高信心、達成更佳臨床結果。

  • On the International front, Q4 case volume of 19,600 cases increased 7.9% sequentially driven, by our core European countries. Specifically, we saw an uptick in Italy, France and Spain as they rebounded from their seasonally slower Q3 summer period while Germany and France continued solid growth.

    在國際市場方面,第四季病例量為 19,600 例,較前一季增加 7.9%,主要由我們歐洲核心國家帶動。具體而言,義大利、法國與西班牙在第三季夏季淡季後回升;同時德國與法國持續穩健成長。

  • On a year-over-year basis, international case volume increased 20.3%, reflecting that good growth from Germany and France, which are benefiting from increased sales force coverage and marketing program investments over the past year. In addition, growth from our distribution partners in the Asia-Pacific, EMEA and Latin America regions continues to outpace the rest of the world and contributed to strong year-over-year growth.

    以年對年來看,國際病例量增加 20.3%,反映德國與法國的良好成長;這些市場受惠於過去一年增加的銷售人力覆蓋與行銷方案投資。此外,我們在亞太、EMEA 與拉丁美洲地區的經銷夥伴成長持續快於世界其他地區,並對強勁的年對年成長有所貢獻。

  • Now let's review the key Invisalign metrics that measure our customer penetration. Utilization rates, or what we call same practice sales of our product, as well as the number of new doctors trained, as we continue to grow our base of submitting practices. Overall, Q4 utilization increased to 4.1 cases per doctor. Utilization among North American GPs increased to 3 cases per doctor.

    現在讓我們檢視衡量客戶滲透率的幾項 Invisalign 關鍵指標。包括使用率(或我們所稱的同一診所對我們產品的銷售量),以及新受訓醫師的人數,因為我們持續擴大提交病例的診所基礎。整體而言,第四季使用率提升至每位醫師 4.1 例。北美 GP 的使用率提升至每位醫師 3 例。

  • Utilization among North American Orthos decreased slightly to 7 cases per doctor reflecting the seasonality in their teen case starts. International doctor utilization increased slightly to 4.1 cases per doctor. During Q4, we trained a total of 1,925 new doctors compared to 1,585 in Q3. In North America, we trained 955 new docs, an increase of 30% from last quarter, as we typically train more GPs after the summer months.

    北美地區的矯正專科醫師(Ortho)每位醫師的使用量小幅下降至每位醫師 7 例,反映其青少年病例啟動的季節性因素。國際地區每位醫師的使用量小幅上升至每位醫師 4.1 例。在第四季,我們共訓練了 1,925 位新醫師,第三季為 1,585 位。在北美,我們訓練了 955 位新醫師,較上季增加 30%,因為我們通常在夏季過後會訓練更多一般牙醫(GP)。

  • Across our international geographies, we trained 970 new doctors, up from the 855 we trained in Q3, and of the newly trained international doctors in Q4, several hundred were trained by our distribution partners in anticipation of full commercial Invisalign launches in Russia and the Middle East. It also reflect our direct efforts to support the continued ramp in China by training some new doctors.

    在我們的各個國際地區,我們訓練了 970 位新醫師,高於第三季訓練的 855 位;而第四季新訓練的國際醫師中,有數百位是由我們的經銷合作夥伴所訓練,以因應俄羅斯與中東地區 Invisalign 全面商業上市的準備。這也反映了我們為支持中國持續放量而直接投入的努力,透過訓練部分新醫師來推動。

  • I'll now turn to an update on our key strategic initiatives and discuss progress in each area. To do that, I'll start with product and clinical innovation by providing a brief update on the launch of Invisalign Express 5. I'll touch on our continued progress in the Teenage Orthodontics segment using all Invisalign products including Invisalign Teen and increased use of Invisalign Assist with newly trained GPs.

    接下來我將更新我們的關鍵策略性計畫,並說明各領域的進展。為此,我將先從產品與臨床創新開始,簡要更新 Invisalign Express 5 的上市情況。我也會談到我們在青少年矯正(Teenage Orthodontics)領域的持續進展,涵蓋所有 Invisalign 產品(包括 Invisalign Teen),以及新受訓一般牙醫(GP)對 Invisalign Assist 使用量的提升。

  • I'll also touch on our efforts to accelerate development for our scanner technology including new software releases, as well as some of the new offerings announced by Straumann and BIOMET 3i. Let's get that started with Invisalign.

    我也會提到我們加速掃描器技術開發的努力,包括新的軟體版本發布,以及 Straumann 與 BIOMET 3i 所宣布的一些新產品/方案。我們就從 Invisalign 開始。

  • We recently announced Invisalign Express 5, a cost effective treatment option for very minor crowding, spacing or Orthodontic relapse treatments requiring 5 or fewer stages of Invisalign aligners. We believe that many patients want to correct a little crowding or other minor malocclusions but don't actually pursue or accept treatment because they believe Orthodontic treatment is too expensive for those minor corrections.

    我們近期宣布推出 Invisalign Express 5,這是一項具成本效益的治療選項,適用於非常輕微的擁擠、間隙,或矯正復發(Orthodontic relapse)治療,且所需 Invisalign 隱形牙套階段數為 5 個或以下。我們相信,許多患者希望矯正些微擁擠或其他輕度咬合不正,但實際上並未追求或接受治療,因為他們認為針對這些小幅修正的矯正治療費用過高。

  • Invisalign Express 5 gives doctors a new option for these patients, and unlike lab-based manually produced aligners, Invisalign Express 5 has all of the cutting edge technology of Invisalign and delivers the benefits of straighter teeth at a price consistent with those minor fixes. Invisalign Express 5 is a shorter duration option to Invisalign Express 10 and is available to our North American customers beginning this week for $549. This product ensures that Align can be a more complete competitor in clear liner therapy by addressing a growing segment with a best in class product at a very competitive price. Since announcing Invisalign Express 5 in early January, initial feedback from customers has been very positive and we are excited about the potential for Invisalign Express 5 in the market.

    Invisalign Express 5 為醫師提供了面向這些患者的新選擇;且不同於以實驗室為基礎、手工製作的牙套,Invisalign Express 5 具備 Invisalign 所有最先進的技術,並以符合小幅修正的價格,提供牙齒更整齊的效益。Invisalign Express 5 的療程時間較 Invisalign Express 10 更短,本週起在北美提供給客戶,價格為 549 美元。透過以極具競爭力的價格、以同級最佳產品切入一個成長中的細分市場,本產品確保 Align 在透明牙套治療領域能成為更完整的競爭者。自 1 月初宣布 Invisalign Express 5 以來,客戶的初步回饋非常正面,我們也對 Invisalign Express 5 在市場上的潛力感到振奮。

  • Now, moving on to the Teenage Orthodontic segment which for us, consists of teenagers 19 and younger using any Invisalign product. Teenagers are still the largest segment of new Orthodontic case starts and they represent a great opportunity for us to continue taking share from existing Wires and Brackets case starts to increase our share of share.

    接著談青少年矯正市場;對我們而言,該市場包含 19 歲及以下、使用任何 Invisalign 產品的青少年。青少年仍是新啟動矯正病例中最大的族群,這也為我們提供了絕佳機會,持續從既有的鋼絲與托槽(Wires and Brackets)病例中取得市占,進一步提升我們的市占率。

  • In Q4, the number of teenagers starting treatment with Invisalign products was 18,140 or 22% of total case volume, as compared to 20,170 or 25.4% of total case volume in Q3. As expected, Teenage cases declined sequentially, reflecting normal seasonality in the Orthodontic market. Q4 Teenage case starts increased 32% year-over-year, compared to 8% in Q4 last year.

    第四季,使用 Invisalign 產品開始治療的青少年人數為 18,140 例,占總病例量 22%;相較之下,第三季為 20,170 例,占總病例量 25.4%。如預期,青少年病例較前一季下滑,反映矯正市場的正常季節性。第四季青少年病例啟動量年增 32%,相較去年第四季為 8%。

  • We had similar trends with the Invisalign Teen product this quarter which declined sequentially, but still grew 41% year-over-year to 9,805 cases. For the full year, total teenagers using Invisalign were 68,885, an increase of 18% from 2010. Overall, we're very pleased with our results in the Teenager segment.

    本季 Invisalign Teen 產品也呈現類似趨勢,雖然較前一季下滑,但仍年增 41% 至 9,805 例。全年而言,使用 Invisalign 的青少年總數為 68,885 人,較 2010 年增加 18%。整體來看,我們對青少年市場的成果非常滿意。

  • Our estimates of current Orthodontic market growth imply a low single digit growth rate and against that framework it appears we are continuing to gain share, while helping to increase category growth over the long-term. We're confident that we'll continue to make steady progress increasing Invisalign's share, especially among the teen population.

    我們對目前矯正市場成長的估計顯示其成長率為低個位數;在此框架下,看起來我們仍持續提升市占,同時也有助於長期提升品類成長。我們有信心將持續穩健推進 Invisalign 市占的提升,尤其是在青少年族群中。

  • Usage of Invisalign Assist, which is designed to help newly trained and lower volume GPs gain confidence using Invisalign, continues to increase steadily, as well. In Q4, Invisalign Assist case shipments were 5,695, an increase of 9% sequentially and 50% from the same quarter last year. 5-0, 50% from the same quarter last year.

    Invisalign Assist 的使用量也持續穩定增加;該方案旨在協助新受訓且病例量較低的一般牙醫(GP)建立使用 Invisalign 的信心。第四季,Invisalign Assist 病例出貨量為 5,695 例,較前一季增加 9%,較去年同期增加 50%。5-0,較去年同期增加 50%。

  • Our integrated consumer marketing platform combines traditional print and broadcast media with a balanced mix of PR, event marketing, and social media. The goal of this consumer platform is to raise awareness of Invisalign and Invisalign Teen as the best options for a healthy, beautiful smile among adults and teens.

    我們整合式的消費者行銷平台,將傳統平面與廣播媒體,與公關(PR)、活動行銷及社群媒體的均衡組合相結合。此消費者平台的目標,是在成人與青少年族群中,提升對 Invisalign 與 Invisalign Teen 的認知,使其被視為打造健康、美麗笑容的最佳選擇。

  • In addition, this platform enables us to help prospective patients find a great practice that can meet their needs. One of the ways we measure progress in this front is through activity on our consumer website where prospective patients can get more information and search for an Invisalign doctor in their area.

    此外,該平台也使我們能協助潛在患者找到能滿足其需求的優質診所。我們衡量此方面進展的方法之一,是觀察消費者網站上的活動情況;潛在患者可在網站上取得更多資訊,並搜尋其所在地區的 Invisalign 醫師。

  • In 2011, we had more than 4 million visits to Invisalign.com with a growing number of leads and ever-improving conversion to patient starts. In Q4, we continued building awareness and demand for Invisalign with this integrated platform although with a significant lower profile in TV advertising due to typical pre-holiday competition for air time and consumer attention.

    2011 年,Invisalign.com 的造訪次數超過 400 萬次,帶來愈來愈多的潛在客戶名單(leads),且轉換為實際啟動治療的轉換率持續改善。第四季,我們持續透過此整合平台建立 Invisalign 的認知與需求,但由於假期前典型的播出時段競爭以及消費者注意力分散,電視廣告的曝光顯著降低。

  • On a public relations front Invisalign was featured in two of the nation's most popular women's lifestyle magazines, Woman's Day and Woman's Health in articles about Best Treatment Options and Age Proofing Your Smile. October provided an opportunity to reach more than 17 million consumer households by focusing on the benefits of Invisalign Teen in two Halloween Tips and Treats satellite media tours.

    在公關方面,Invisalign 於全國最受歡迎的兩本女性生活風格雜誌《Woman's Day》與《Woman's Health》中亮相,相關文章主題包括「最佳治療選項」與「讓你的笑容凍齡」。10 月則透過兩場以萬聖節「Tips and Treats」為主題的衛星媒體巡迴(satellite media tours),聚焦 Invisalign Teen 的效益,觸及超過 1,700 萬戶消費者家庭。

  • On the digital and social media front, we continued our campaign to develop valuable online advocates and social media content through our Invisalign mount advisory board and blogger events across North America, including a successful Invisalign Teen campaign targeting Canadian moms.

    在數位與社群媒體方面,我們持續推動行銷活動,透過 Invisalign 媽媽顧問委員會(mom advisory board)以及北美各地的部落客活動,培養有價值的線上倡議者與社群內容,其中也包括一項成功的 Invisalign Teen 活動,鎖定加拿大媽媽族群。

  • As for event marketing, in December we wrapped up the Disney's Next Big Thing tour sponsored by Invisalign Teen. The tour gave local doctors and Invisalign reps in each market the opportunity to engage with thousands of parent and kids at each event, and created millions of media and online impressions through its related traditional PR and social media aspects. Moving forward into Q1, we are stepping up our media spend with national and cable TV advertising, primarily focused on moms and teens and expanding our presence in top markets with radio advertising to complement our TV ads.

    在活動行銷方面,12 月我們完成了由 Invisalign Teen 贊助的 Disney's Next Big Thing 巡迴活動。該巡迴活動讓各市場的在地醫師與 Invisalign 業務代表有機會在每場活動中與數千名家長與孩子互動,並透過相關的傳統公關與社群媒體面向,創造數百萬次媒體與線上曝光(impressions)。展望第一季,我們將提高媒體投放,包含全國性與有線電視廣告,主要聚焦媽媽與青少年;同時在重點市場擴大電台廣告投放,以補強電視廣告。

  • Turning now to International. Our continued growth in these geographies requires us to integrate all of our strategic initiatives, particularly technology and product innovation, which helps doctors treat more complex cases. In addition, we are very focused on enhancing the customer experience, sales effectiveness and professional education programs across all our direct geographies.

    接下來談國際市場。我們在這些地區的持續成長,需要整合所有策略性計畫,尤其是技術與產品創新,以協助醫師治療更複雜的病例。此外,我們也非常專注於在所有直營地區提升客戶體驗、銷售效能與專業教育計畫。

  • The good news here; Europe and other regions are even more underpenetrated than North American for both Invisalign and Orthodontic treatment, and the cases they treat are more complex. For that reason, we believe that Invisalign G3 and G4 will continue to support growth into these markets with those more difficult cases.

    好消息是:歐洲及其他地區在 Invisalign 與矯正治療兩方面的滲透率都比北美更低,而其治療的病例也更為複雜。因此,我們相信 Invisalign G3 與 G4 將持續支持我們在這些市場的成長,並有助於處理那些更具挑戰性的病例。

  • When we factor in the economic headwinds in Europe into these opportunities, it has motivated us to accelerate some of our planned evolution in sales coverage, sales and marketing efficiency, clinical education and the Invisalign platform itself that we went through several years ago in the US.

    當我們將歐洲的經濟逆風納入這些機會的考量時,這促使我們加速推進部分原先規劃的演進,包括銷售覆蓋、銷售與行銷效率、臨床教育,以及 Invisalign 平台本身——這些我們在數年前已於美國推動過。

  • We're still early in this process, but are seeing positive signs of progress and are confident we can drive growth here. Outside of Europe, Japan continues to exhibit solid growth albeit on a small base. In China, our newest direct country market, we continue to make progress on executing our strategy of working initially with the key opinion leaders and leading public and private doctors.

    我們仍處於這個流程的早期階段,但已看到正向的進展跡象,並有信心能在此推動成長。在歐洲以外,日本持續展現穩健成長,儘管基期仍小。在中國——我們最新的直營國家市場——我們持續在執行策略上取得進展,初期先與關鍵意見領袖(KOL)以及領先的公立與民營醫師合作。

  • To that end, the fourth quarter capped off a very successful inaugural year for Invisalign in China. During Q4, we hosted several well-attended Invisalign Orthodontists' lectures in the key hospitals for our four core target cities, and we held additional Invisalign training courses for opinion leaders and other key doctors.

    為此,第四季為 Invisalign 在中國非常成功的首個年度畫下句點。在第四季期間,我們在四個核心目標城市的重點醫院舉辦了多場出席踴躍的 Invisalign 矯正醫師講座,並為意見領袖及其他關鍵醫師加開了 Invisalign 訓練課程。

  • We also made advancements in getting Invisalign entered into the pricing system of major public hospitals. Finally, while still on a very small base, we received more initial and follow-on cases from early influential users.

    我們也在推動 Invisalign 納入主要公立醫院定價系統方面取得進展。最後,雖然基期仍非常小,我們從早期具影響力的使用者那裡收到更多初始病例與後續追加病例。

  • In Q1, we'll continue to focus on execution of our KOL focus strategy and continue heavy clinical education and support for our practitioners. Overall, the level of interest and encouragement and engagement among doctors who are advocating for Invisalign is strong. I'll keep you posted on our continued progress there.

    在第一季,我們將持續聚焦於執行 KOL 聚焦策略,並持續為臨床醫師提供大量的臨床教育與支援。整體而言,倡議 Invisalign 的醫師群體之興趣、鼓勵與參與度都很強。我會持續向各位更新我們在當地的進展。

  • We've also continue to expand our base internationally through entry into new countries using distribution partners to cover these smaller, but still very important country markets of Asia-Pacific, EMEA and Latin America. Collectively, they continue to make very good progress, and represent 14% of international Invisalign revenue, with growth rates outpacing those of Europe and North America.

    我們也持續透過與經銷合作夥伴進入新國家來擴大國際基礎,以覆蓋亞太、EMEA 與拉丁美洲這些規模較小但仍非常重要的國家市場。整體而言,這些市場持續取得非常良好的進展,並占國際 Invisalign 營收的 14%,其成長率也超越歐洲與北美。

  • We recently launched Invisalign in the Middle East and received regulatory approval in Russia which we announced earlier this month. On a smaller scale, we have good efforts going on in Brazil and Argentina, places that should be a good fit for the Invisalign value proposition for both practitioners and patients.

    我們近期在中東推出 Invisalign,並在俄羅斯取得監管核准,我們已於本月稍早對外宣布。在較小規模方面,我們在巴西與阿根廷也有良好的推進,這些地方對 Invisalign 的價值主張而言,無論對臨床醫師或患者都應相當契合。

  • We have great opportunities in these other regions and while individually these are smaller in scale, collectively they represent great long-term opportunity. While we're still far behind North America in terms of Orthodontic and Invisalign penetration, it just means we have greater headroom for future growth in all these geographies.

    我們在其他地區擁有很好的機會;雖然單一市場規模較小,但合計而言代表極佳的長期機會。雖然在矯正與 Invisalign 滲透率方面我們仍遠落後於北美,但這也意味著在所有這些地理市場中,我們未來成長的上行空間更大。

  • Moving on to our scanner and CAD/CAM services products. Q4 revenues for both was $10 million compared to $11.6 million in Q3. Q4 scanner sales were $5.2 million compared to $5.4 million in Q3. Q4 CAD/CAM service sales were $4.7 million compared to $6.2 million in Q3. The sequential decrease in Q4 revenue reflects lower than expected scanner sales in Europe, based on lower procedure volume and lab activity, as well as lower scanner-related CAD/CAM services.

    接著談我們的掃描器與 CAD/CAM 服務產品。第四季兩者合計營收為 1,000 萬美元,較第三季的 1,160 萬美元下降。第四季掃描器銷售為 520 萬美元,較第三季的 540 萬美元略降。第四季 CAD/CAM 服務銷售為 470 萬美元,較第三季的 620 萬美元下降。第四季營收的季減主要反映歐洲掃描器銷售低於預期(受較低的療程量與技工所活動影響),以及與掃描器相關的 CAD/CAM 服務減少。

  • In North America, scanner sales continued to benefit from leveraging our sales and marketing resources including Invisalign and industry events to introduce scanners to our customers. We generated a lot of interest for iTero scanners at the American Dental Association meeting in Los Vegas in October, as well as the Greater New York Dental Show at the end of November. Overall we are doing better than our original expectations in North America, but yet not enough to offset the softness in Europe.

    在北美,掃描器銷售持續受惠於我們運用銷售與行銷資源(包括 Invisalign 與產業活動)向客戶介紹掃描器。我們在 10 月於拉斯維加斯舉行的美國牙科協會(ADA)年會,以及 11 月底的大紐約牙科展上,為 iTero 掃描器帶來了大量關注。整體而言,我們在北美的表現優於原先預期,但仍不足以抵消歐洲市場的疲弱。

  • Part of the reason for that solid performance was our progress in the technology. In December, we announced a significant software enhancement for the iTero 3D scanning system using dental practices for a wide range of restorative dental procedures. The latest version of iTero software includes the Invisalign scanning protocol for full interoperability with Invisalign treatment, including links to the Invisalign doctor site and the Invisalign case gallery for patient education.

    這項穩健表現的部分原因,是我們在技術上的進展。12 月,我們宣布 iTero 3D 掃描系統的一項重大軟體強化,使牙科診所可用於更廣泛的修復牙科療程。最新版 iTero 軟體包含 Invisalign 掃描流程,可與 Invisalign 治療完全互通,包括連結至 Invisalign 醫師網站與 Invisalign 病例圖庫,以用於患者教育。

  • It also includes important enhancements of software tools that will help deliver faster, more accurate 3D impressions of the patient's dentition and greater efficiency for iTero customers. The value proposition for intra-oral scanning for GP dentists remain compelling. As we've described before, GPs primarily do restorative work that makes up the majority of their day-to-day workflow. When it comes time for GPs to start an Orthodontic case, they have to switch gears to Ortho-mode.

    此外也包含重要的軟體工具強化,可協助更快速、更精準地取得患者齒列的 3D 印模,並提升 iTero 客戶的效率。口內掃描對一般牙科醫師(GP)的價值主張仍然相當具吸引力。如同我們先前所述,GP 主要從事修復治療,這占其日常工作流程的大多數。當 GP 要開始一個矯正病例時,就必須切換到矯正模式。

  • They stop what they're doing on all the restorative work and re-calibrate their office and staff around a procedure they still do infrequently. To help make it easier for them, we are developing chair-side applications to run on our intra-oral scanning systems for use with Invisalign treatment.

    他們必須暫停手上所有修復治療工作,並重新調整診所與人員配置,以配合一項他們仍較少進行的療程。為了讓他們更容易上手,我們正在開發可在口內掃描系統上運行、用於 Invisalign 治療的椅旁應用程式。

  • The goal is to enhance Invisalign case assessment and treatment planning by bringing digital tools chair-side in the practice. Providing real time chair-side applications on our scanners will make it much easier for GPs to set up an Invisalign case, discuss the scope of treatment and set expectations with the patient.

    目標是透過在診所椅旁導入數位工具,強化 Invisalign 病例評估與治療規劃。在我們的掃描器上提供即時椅旁應用程式,將使 GP 更容易建立 Invisalign 病例、與患者討論治療範圍並設定治療預期。

  • During 2012, we'll start rolling out these chair-side applications to begin helping our lower volume doctors integrate these tools into their practices in a way that complements their existing workflow in the office. Our first chair-side application is currently in beta testing with a small number of North American GPs.

    在 2012 年期間,我們將開始逐步推出這些椅旁應用程式,協助低病例量的醫師以能配合其既有診所工作流程的方式,將這些工具整合進其執業中。我們的第一個椅旁應用程式目前正與少數北美 GP 進行 Beta 測試。

  • We'll start to wrap up this beta test soon, then begin collecting and analysing feedback in preparation for a commercial launch this summer. Among our core Invisalign Orthodontist customers, we are leveraging our direct sales force and also utilizing established customer events like our series of Invisalign Regional Ortho forums to help drive sales of iOC scanners.

    我們將很快結束這項 Beta 測試,接著開始蒐集並分析回饋,以為今年夏季的商業化上市做準備。在我們核心的 Invisalign 矯正醫師客群中,我們運用直營銷售團隊,並利用既有的客戶活動(例如一系列 Invisalign 區域矯正論壇)來推動 iOC 掃描器的銷售。

  • This is especially attractive for those Ortho customers who are looking to differentiate their practices by further integrating digital technology such as intra-oral scanners and replacing the cost and unpleasant experience of PVS impressions altogether. This trend towards accelerating digitization is very positive, as we have been one of the very few treatment modalities in dentistry that rely fully upon digital technologies. As the Invisalign process is improved for our customers, more and more initial Invisalign case submissions are transmitted to us on a digital basis, including digital records like x-rays and photos and treatment plan, except for the physical PVS impressions themselves.

    這對於希望透過進一步整合口內掃描器等數位技術、並全面取代 PVS 印模的成本與不舒適體驗,以差異化其診所的矯正客戶而言尤其具吸引力。這股加速數位化的趨勢非常正面,因為我們一直是牙科領域中少數完全依賴數位技術的治療模式之一。隨著 Invisalign 流程對客戶持續改善,越來越多初始 Invisalign 病例提交以數位方式傳送給我們,包括 X 光、照片與治療計畫等數位紀錄——唯獨仍不含實體 PVS 印模。

  • Approximately 80% of our incoming Invisalign case submissions now are fully digital except for those PVS impressions, which patients consistently report is the worst part of their otherwise wonderful Invisalign experience. Since making interoperability with Invisalign available on iOC in May, we've seen digital impressions begin to replace traditional PVS impressions among Ortho practices with our scanner.

    目前我們收到的 Invisalign 病例提交中,約有 80% 除了 PVS 印模之外皆為全數位化;而患者一再反映,PVS 印模是他們原本非常良好的 Invisalign 體驗中最糟的一部分。自 5 月在 iOC 上提供與 Invisalign 的互通性以來,我們已看到在配備我們掃描器的矯正診所中,數位印模開始取代傳統 PVS 印模。

  • In fact, of the 80% of the cases I just referenced, 6% of them now are fully digital and include that IOS digital impression instead of a PVS impression. This trend is positive for both Align and our customers as they get their ClinCheck and final cases faster with less hassle for patients, and all reports to date indicate aligner fit is even better.

    事實上,在我剛提到的那 80% 病例中,現在有 6% 已是完全數位化,並以 IOS 口內掃描的數位印模取代 PVS 印模。這一趨勢對 Align 與我們的客戶皆為正面,因為他們能更快取得 ClinCheck 與最終病例結果、患者也更省事;且截至目前的回報顯示,隱形牙套的貼合度甚至更好。

  • Straumann, our distribution partner in Europe and BIOMET 3i are both leaders in dental implants. They each provide custom dental implant abutment solutions on the iTero scanner and because we have an open architecture platform anyone can use what we call our STL files. That means the customers can export our STL digital files to any third party lab of choice for additional restorative options. We've entered into a limited market release for the Straumann Implant Analog Digital Workflow.

    Straumann(我們在歐洲的經銷合作夥伴)與 BIOMET 3i 皆為牙科植體領域的領導者。他們各自都在 iTero 掃描器上提供客製化植體基台解決方案;由於我們採用開放式架構平台,任何人都可以使用我們所稱的 STL 檔案。這表示客戶可以將我們的 STL 數位檔案匯出至任何選定的第三方技工所,以取得更多修復選項。我們已針對 Straumann 植體類比體數位工作流程(Straumann Implant Analog Digital Workflow)進行有限市場發佈。

  • This workflow allows oral surgeons, periodontists and general dentists the ability to take an iTero scan of the Straumann scan body and utilize a stock Straumann repositionable analog and abutment to complete the restoration. This new digital workflow gives the clinician open choice to utilize the Straumann digital workflow with custom and stock abutments. We expect the analog workflow to be in general availability in the near future.

    此工作流程讓口腔外科醫師、牙周病專科醫師與一般牙醫能夠對 Straumann 掃描體(scan body)進行 iTero 掃描,並使用標準(stock)的 Straumann 可重新定位類比體(repositionable analog)與基台(abutment)來完成修復體。這項新的數位工作流程讓臨床醫師可開放選擇使用 Straumann 的數位工作流程,搭配客製與標準基台。我們預期類比體工作流程將在不久的將來全面上市。

  • Beyond these product initiatives, we continue to work with the Straumann team on re-staging growth in their European territory. We are also continuing to actively collaborate with BIOMET 3i to support their BellaTek Encode digital workflow with the iTero scanner.

    除了這些產品計畫之外,我們也持續與 Straumann 團隊合作,重新推動其歐洲區域的成長。我們也持續積極與 BIOMET 3i 協作,以 iTero 掃描儀支援其 BellaTek Encode 數位工作流程。

  • Our collaborative educational and marketing events are providing exciting opportunities for BIOMET 3i implant customers to adopt the new digital workflow with iTero. We expect this collaboration within our field sales and marketing teams to grow over the coming months with expansion of our iTero field sales team.

    我們共同舉辦的教育與行銷活動,正為 BIOMET 3i 植體客戶採用 iTero 的新數位工作流程提供令人振奮的機會。隨著我們擴編 iTero 外勤銷售團隊,我們預期未來幾個月內,外勤銷售與行銷團隊之間的合作將持續成長。

  • I'll now turn the call over to Ken for more detail on our fourth quarter financials and our outlook for Q1 and then I'll come back for a few closing remarks. Ken?

    接下來我會把電話會議交給 Ken,請他更詳細說明我們第四季的財務表現以及對第一季(Q1)的展望,之後我會再回來做幾點結語。Ken?

  • - VP, CFO

    - VP, CFO

  • Thanks, Tom. Before I get started with the financial results, I would like to comment on a few items. First, to provide greater transparency to the underlying performance of Invisalign and the scanner and CAD/CAM services, beginning this quarter we will include in our earnings release a breakdown of revenue and gross margin for both segments of the Business. Second, I would like to remind everybody that for comparative purposes, our 2011 financial results include eight months of scanner and CAD/CAM services.

    謝謝你,Tom。在我開始說明財務結果之前,我想先就幾個事項做些評論。第一,為了讓 Invisalign 以及掃描儀與 CAD/CAM 服務的基礎表現更透明,自本季起,我們將在盈餘新聞稿中納入兩個業務部門的營收與毛利率拆分。第二,我想提醒各位,為了可比性,我們 2011 年的財務結果包含掃描儀與 CAD/CAM 服務八個月的業績。

  • Finally, there are several items that we exclude from our GAAP results when we report non-GAAP results. For 2011, these include acquisition-related costs, amortization of intangible assets, integration costs and severance and benefits costs for the New Jersey consolidation. For our discussion today on the conference call, I will not review the total dollars excluded for non-GAAP gross margin, operating expenses and operating margin, and instead will refer you to our press release tables, reconciliation of GAAP to non-GAAP key financial metrics, and the business outlook summary for a complete reconciliation.

    最後,當我們報告非 GAAP 結果時,會從 GAAP 結果中排除若干項目。就 2011 年而言,這些項目包括併購相關成本、無形資產攤銷、整合成本,以及新澤西整併所產生的資遣與福利成本。在今天的電話會議討論中,我不會逐一檢視為非 GAAP 毛利、營業費用與營業利益率所排除的總金額,而是請各位參考我們新聞稿表格、GAAP 與非 GAAP 主要財務指標的調節表,以及業務展望摘要,以取得完整調節資訊。

  • Now, let's review our fourth quarter financial results beginning with revenue. Q4 net revenue was a total of $128.9 million, which consisted of Invisalign revenue of $118.9 million, and scanner and CAD/CAM services revenue of $10 million. This is a sequential increase of 2.4% from $125.9 million in Quarter Three 2011 and a year-over-year increase of 38.8% from $92.9 million in Q4 2010.

    現在,讓我們從營收開始回顧第四季財務結果。第四季(Q4)淨營收合計為 1.289 億美元,其中 Invisalign 營收為 1.189 億美元,掃描儀與 CAD/CAM 服務營收為 1,000 萬美元。相較 2011 年第三季的 1.259 億美元,季增 2.4%;相較 2010 年第四季的 9,290 萬美元,年增 38.8%。

  • Q4 Invisalign revenue of $118.9 million increased to 4.1%, compared to Q3 revenue of $114.3 million, an increase to 28%, compared to Q4 2010 revenue of $92.9 million. The sequential increase in Q4 revenue reflects increased North American GP and International case volumes.

    第四季 Invisalign 營收為 1.189 億美元,較第三季的 1.143 億美元增加 4.1%;較 2010 年第四季的 9,290 萬美元增加 28%。第四季營收的季增,反映北美一般牙醫(GP)與國際病例量增加。

  • This volume growth was partially offset by lower ASPs driven by foreign exchange rates as the dollar strengthened against the Euro, and increased advantage rebates, as a record number of doctors received rebates and are moving up in the program tiers. On a year-over-year basis, Q4 Invisalign revenue growth was driven primarily by higher volumes across all customer channels. In Q4, scanner and CAD/CAM service revenue of $10 million decreased slightly from $11.6 million in Q3.

    此一量的成長部分被較低的平均售價(ASP)所抵銷;平均售價下降主要受匯率影響,因美元兌歐元走強,以及 advantage 回饋(rebates)增加所致,因為創紀錄數量的醫師獲得回饋並在方案等級中升級。以年對年來看,第四季 Invisalign 營收成長主要由各客戶通路的較高出貨量所帶動。第四季掃描儀與 CAD/CAM 服務營收為 1,000 萬美元,較第三季的 1,160 萬美元略為下降。

  • Moving on to gross margin and operating expenses. Q4 GAAP gross margin was $95.6 million or 74.1%. This compares to $92.4 million or 73.4% in Q3 and $71.8 million or 77.2% in the same quarter last year. Q4 GAAP gross margin for Invisalign was 78.7% and scanner and CAD/CAM services was 20%. This compares to 78.6% and 21.5% respectively in quarter three.

    接著看毛利與營業費用。第四季 GAAP 毛利為 9,560 萬美元,毛利率 74.1%。相較之下,第三季為 9,240 萬美元、毛利率 73.4%;去年同期為 7,180 萬美元、毛利率 77.2%。第四季 Invisalign 的 GAAP 毛利率為 78.7%,掃描儀與 CAD/CAM 服務為 20%。相較第三季分別為 78.6% 與 21.5%。

  • Non-GAAP gross margin for Quarter Four was $96.6 million or 74.9%. This compares to non-GAAP gross margin of $93 million, or 73.9% in Quarter Three and there was no difference between GAAP and non-GAAP gross margin for Q4 2010. For Invisalign, there was no difference between GAAP and non-GAAP gross margin for Quarter Four and Quarter Three of 2011 and Quarter Four of 2010.

    第四季非 GAAP 毛利為 9,660 萬美元,毛利率 74.9%。相較第三季非 GAAP 毛利為 9,300 萬美元、毛利率 73.9%;而 2010 年第四季 GAAP 與非 GAAP 毛利並無差異。就 Invisalign 而言,2011 年第四季與第三季以及 2010 年第四季,GAAP 與非 GAAP 毛利亦無差異。

  • Q4 non-GAAP scanner and CAD/CAM services gross margin was 30% compared to 27.1% last quarter. The sequential increase in Q4 non-GAAP gross margin primarily reflects the increased case volume of Invisalign, which was partially offset by foreign exchange rates and advantage rebates.

    第四季非 GAAP 掃描儀與 CAD/CAM 服務毛利率為 30%,高於上季的 27.1%。第四季非 GAAP 毛利率的季增,主要反映 Invisalign 病例量增加,但部分被匯率與 advantage 回饋所抵銷。

  • Q4 GAAP operating expense was $69.1 million. This compares to GAAP operating expense of $66.1 million in Quarter Three and $57 million in the same quarter last year. Q4 non-GAAP operating expense was $66.9 million. This compares to $63.8 million in Quarter Three and $55.7 million in the same quarter last year.

    第四季 GAAP 營業費用為 6,910 萬美元。相較第三季 GAAP 營業費用為 6,610 萬美元,去年同期為 5,700 萬美元。第四季非 GAAP 營業費用為 6,690 萬美元。相較第三季為 6,380 萬美元,去年同期為 5,570 萬美元。

  • The sequential increase in Q4 non-GAAP operating expense was primarily driven by the full quarter's effect from additions to our sales force, including North American scanner sales headcount, the implementation of marketing programs in both North America and international, and cost to commercialize Invisalign G4.

    第四季非 GAAP 營業費用的季增,主要由銷售團隊擴編的整季效應所帶動,其中包括北美掃描儀銷售人力;同時也包括在北美與國際市場推行行銷方案,以及將 Invisalign G4 商業化的成本。

  • Q4 GAAP operating income was $26.4 million, this compares to GAAP operating income of $26.3 million in Q3 and $14.8 million in the same quarter a year ago. Q4 non-GAAP operating income was $29.7 million or 23%. This compares to $29.2 million or 23.2% in Quarter Three and $16 million or 17.2% in the same quarter last year.

    第四季 GAAP 營業利益為 2,640 萬美元;相較第三季 GAAP 營業利益為 2,630 萬美元,去年同期為 1,480 萬美元。第四季非 GAAP 營業利益為 2,970 萬美元,營業利益率 23%。相較第三季為 2,920 萬美元、營業利益率 23.2%;去年同期為 1,600 萬美元、營業利益率 17.2%。

  • Q4 GAAP diluted earnings per share was $0.25 compared to $0.24 in Quarter Three and $0.13 in the same quarter last year. Q4 non-GAAP earnings per share was $0.28 compared to $0.27 in Quarter Three and $0.14 in Q4 of last year.

    第四季 GAAP 稀釋每股盈餘為 0.25 美元,相較第三季為 0.24 美元,去年同期為 0.13 美元。第四季非 GAAP 每股盈餘為 0.28 美元,相較第三季為 0.27 美元,去年第四季為 0.14 美元。

  • Now let's move on to the balance sheet. Cash, cash equivalents and marketable securities were $248.1 million. This is compared to $312.4 million at the end of 2010. In Q4, we generated roughly $42.3 million in cash from operations. This is compared to $41.6 million in Q3 and $32.5 million in the same quarter last year. In Q4, DSOs were 64 days compared to 62 days in Quarter Three and 63 days in the same quarter last year.

    現在我們來看資產負債表。現金、約當現金與有價證券為 2.481 億美元。相較 2010 年底為 3.124 億美元。第四季我們由營運活動產生約 4,230 萬美元現金。相較第三季為 4,160 萬美元,去年同期為 3,250 萬美元。第四季應收帳款週轉天數(DSO)為 64 天,相較第三季為 62 天,去年同期為 63 天。

  • As you may recall, last quarter we announced that our Board of Directors had authorized a stock repurchase program up to $150 million. At the end of Quarter Four, we repurchased approximately 300,000 shares at an average price of $24 per share for a total of $7.8 million. We have $142.2 million remaining under the authorization.

    各位可能還記得,上季我們宣布董事會已核准最高 1.5 億美元的庫藏股回購計畫。截至第四季末,我們以每股平均 24 美元回購約 30 萬股,總金額 780 萬美元。在該授權額度下,尚餘 1.422 億美元可用。

  • Before I move on to the Q1 outlook, I would like to make a few comments the fiscal year results. On a full year basis, revenue was a record $479.7 million, up 23.9% compared to $387.1 million in 2010. Recall that 2010 included a one-time favorable impact of $14.3 million for previously deferred Teen revenues.

    在我繼續談第一季展望之前,我想先就本財政年度的業績結果做幾點說明。以全年計,營收創下4.797億美元的歷史新高,較2010年的3.871億美元成長23.9%。請記得,2010年包含一筆一次性的有利影響,金額為1,430萬美元,係先前遞延的Teen營收所致。

  • Invisalign revenue of $451.7 million was up 16.7% year-over-year and reflects growth across all customer channels. Scanner and CAD/CAM services added $28 million for the eight months of 2011. GAAP operating income for the year was $90.4 million or 18.8% compared to $102.7 million or 26.5% in 2010.

    Invisalign營收為4.517億美元,年增16.7%,反映各客戶通路皆有成長。掃描器與CAD/CAM服務在2011年的八個月期間貢獻2,800萬美元。全年GAAP營業利益為9,040萬美元(營業利益率18.8%),相較2010年為1.027億美元(營業利益率26.5%)。

  • Non-GAAP operating income for the year was $104.7 million, or 21.8%, compared to $85.1 million or 22.8% in 2010. Our GAAP diluted earnings per share was $0.83 for 2011, compared to $0.95 for 2010, and non-GAAP earnings per share was $0.97 compared to $0.80 in 2010. For the full year, we generated approximately $130.7 million in cash from operations, and this is compared to $120.5 million in 2010.

    全年非GAAP營業利益為1.047億美元(營業利益率21.8%),相較2010年為8,510萬美元(營業利益率22.8%)。我們2011年GAAP稀釋每股盈餘為0.83美元,2010年為0.95美元;非GAAP每股盈餘為0.97美元,2010年為0.80美元。全年我們由營運活動產生約1.307億美元現金,2010年為1.205億美元。

  • Overall, we are pleased with the continued progress in the business and financial performance for the year. The solid non-GAAP operating margin of 21.8% reflects continued strong underlying performance of the Invisalign business while investing in the scanner and CAD/CAM service business to deliver long-term value.

    整體而言,我們對本年度業務持續推進以及財務表現感到滿意。穩健的非GAAP營業利益率21.8%,反映Invisalign業務持續強勁的基本面表現,同時我們也投資於掃描器與CAD/CAM服務業務,以創造長期價值。

  • Despite a challenging economy in Europe and North America, we have continued our focus and execution of our strategic initiatives and demonstrated our ability to grow the top line. Now let's move on to our business outlook for Q1 2012. 2012 is off to a good start with patient flow in North America doctors offices remaining healthy. For Q1 we expect revenues to be in a range of $125.4 million to $127.9 million. The Invisalign case volume is expected to be in a range of 82,500 to 84,000 cases.

    儘管歐洲與北美的經濟環境充滿挑戰,我們仍持續聚焦並落實策略性計畫,並展現出推動營收成長的能力。接下來談談我們對2012年第一季的業務展望。2012年開局良好,北美醫師診所的病患流量仍維持健康水準。第一季我們預期營收介於1.254億至1.279億美元。Invisalign病例量預期介於82,500至84,000例。

  • I would like to take a moment here to point to a few factors that inform our view of Quarter One, as well as how to compare Q4 to the Q1 revenue projections. For Invisalign, the typical seasonality we see for both North America Orthos and GPs is for case volume to increase sequentially.

    我想在此花點時間指出幾項影響我們對第一季看法的因素,以及如何將第四季與第一季營收預測進行比較。就Invisalign而言,我們在北美矯正專科(Orthos)與一般牙科(GPs)所觀察到的典型季節性,是病例量會呈現逐季增加。

  • For international, Q4 is generally their strongest quarter and Q1 is typically down a bit, especially in Europe, with fewer in-office days for doctors due to holiday schedules. In addition to these seasonal trends in the business, we expect recent movements in the Euro to have downward pressure on International ASPs. Also, with continued progress in utilization growth, we expect to see higher levels of advantage rebates in Quarter One.

    就國際市場而言,第四季通常是最強的一季,而第一季通常會略為下滑,尤其在歐洲,因假期安排導致醫師在診天數較少。除上述季節性趨勢外,我們預期近期歐元匯率波動將對國際ASP(平均銷售單價)造成下行壓力。此外,隨著使用率成長持續推進,我們預期第一季的advantage回饋(rebates)水準將更高。

  • Finally, while customers in North America and Europe report steady patient flow in their offices, we continue to be thoughtful about near-term consumer sentiment and the impact on dental visits and high-valued procedures like Invisalign, particularly in Europe. On the scanner and CAD/CAM services side of the business, while it is newer to us and we have not experienced a full annual cycle, Q4 is typically the strongest quarter for dentists and specialists to purchase capital equipment.

    最後,儘管北美與歐洲的客戶回報其診所病患流量穩定,我們仍會審慎看待短期消費者信心及其對牙科就診與如Invisalign等高單價療程的影響,尤其是在歐洲。在掃描器與CAD/CAM服務業務方面,由於這對我們而言仍屬較新的業務且尚未經歷完整年度循環,第四季通常是牙醫與專科醫師購買資本設備最強的一季。

  • As such, we would expect Q1 to be down sequentially. In addition, we continue to focus on how to re-stage growth in Europe and are working with our distribution partners to make that happen.

    因此,我們預期第一季將較前一季下滑。此外,我們持續聚焦於如何在歐洲重新推動成長,並正與我們的經銷合作夥伴合作以促成此事。

  • Now let's move onto gross margin. We expect Q1 GAAP gross margin to be in a range of 72.1% to 73.3% and we expect non-GAAP gross margin to be in a range of 72.7% to 73.9%. The benefits to gross margin from an Invisalign case volume are expected to be offset by the anticipated impacts from foreign exchange rates and advantage rebates just mentioned.

    接下來談毛利率。我們預期第一季GAAP毛利率介於72.1%至73.3%,非GAAP毛利率介於72.7%至73.9%。Invisalign病例量帶來的毛利率效益,預期將被前述外匯匯率與advantage回饋的影響所抵銷。

  • In addition, we are continuing to incur transition costs in cost of goods sold and operating expenses as we move scanner and CAD/CAM services operations from New Jersey to Juarez and Costa Rica. In Q1, we expect GAAP operating expense to be in a range of $71.4 million to $72.7 million. We expect non-GAAP operating expenses to be in a range of $69.7 million to $71 million.

    此外,隨著我們將掃描器與CAD/CAM服務營運自新澤西移轉至華雷斯(Juarez)與哥斯大黎加,我們在銷貨成本與營業費用中仍將持續發生轉移成本。第一季我們預期GAAP營業費用介於7,140萬至7,270萬美元。我們預期非GAAP營業費用介於6,970萬至7,100萬美元。

  • The sequential increase in non-GAAP operating expense reflects increased media spend in Quarter One after being off fare for much of the fourth quarter and annual increases in employee compensation and benefits programs. We expect Q1 GAAP operating margin to be in a range of 15.2% to 16.4%, and GAAP earnings per share to be in the range of $0.17 to $0.19.

    非GAAP營業費用的逐季增加,反映第一季媒體投放支出增加(第四季大部分時間投放較少),以及員工薪酬與福利方案的年度調升。我們預期第一季GAAP營業利益率介於15.2%至16.4%,GAAP每股盈餘介於0.17至0.19美元。

  • We expect Q1 non-GAAP operating margin to be in range of 17.1% to 18.4% and non-GAAP earnings per share to be in the range of $0.19 to $0.21. In Q1, we expect the effective tax rate to be approximately 26%, diluted shares outstanding to be approximately $81 million, and cash on hand to be in the range of $250 million to $255 million, excluding any stock repurchases during the Quarter.

    我們預期第一季非GAAP營業利益率介於17.1%至18.4%,非GAAP每股盈餘介於0.19至0.21美元。第一季我們預期有效稅率約為26%,稀釋流通股數約為8,100萬股,期末現金約介於2.50億至2.55億美元(不含本季任何庫藏股回購)。

  • Now I would like to transition to provide some directional comments and perspective on the full year 2012. From a revenue perspective, we plan on continuing to execute on our Invisalign and scanner and CAD/CAM services strategy. We believe the evolution of the Invisalign product platform, including Invisalign G4 and Invisalign Express 5, we will continue to make progress in adoption growth and drive Invisalign volumes and share gains during the year.

    接下來我想轉而就2012年全年提供一些方向性的評論與觀點。就營收而言,我們計畫持續執行Invisalign以及掃描器與CAD/CAM服務的策略。我們相信Invisalign產品平台的演進(包括Invisalign G4與Invisalign Express 5)將使我們在採用率成長方面持續取得進展,並在全年推動Invisalign量能成長與市占提升。

  • We anticipate this expected increase in adoption and utilization will lead to higher levels of participation in the advantage rebate program. We also believe we'll be facing stronger headwinds from foreign exchange rates in 2012, which, along with increasing advantage rebates, will impact ASPs. We've also been implementing an aggressive plan to enhance our scanner and CAD/CAM services business.

    我們預期採用率與使用率的提升,將帶來advantage回饋計畫更高的參與水準。我們也認為2012年將面臨更強的外匯逆風;此外,外匯因素加上advantage回饋增加,將影響ASP(平均銷售單價)。我們也正在推動一項積極計畫,以強化我們的掃描器與CAD/CAM服務業務。

  • As part of that plan, we have now completed the hiring of the North American scanner sales team and delivered Invisalign interoperability for the iOC and iTero scanners. We believe scanner sales in North America will continue to be solid, and as I've already described expect Europe to be off a bit.

    作為該計畫的一部分,我們現已完成北美掃描器銷售團隊的招募,並已為iOC與iTero掃描器提供Invisalign互通性。我們認為北美掃描器銷售將持續穩健,而如我先前所述,預期歐洲將略為走弱。

  • Moving onto gross margins. As mentioned, we are in the midst of moving the scanner and CAD/CAM service operations from New Jersey to Juarez and Costa Rica, and will be incurring transition costs in cost of goods sold and operating expenses now through the third quarter of 2012. Until we complete the New Jersey consolidation and the move of the aligner fabrications to our new facility in Juarez,we would expect gross margin to remain at the lower end, or slightly below our long-term range of 73% to 78%.

    接下來談毛利率。如前所述,我們正將掃描器與CAD/CAM服務營運自新澤西移轉至華雷斯與哥斯大黎加,並將在2012年第三季前於銷貨成本與營業費用中持續發生轉移成本。在我們完成新澤西整併,以及將矯正器製造移轉至華雷斯新廠之前,我們預期毛利率將維持在較低端,或略低於我們長期目標區間73%至78%。

  • In addition, other elements that can impact our gross margin structure, either positive or negative, are significant shifts in Invisalign case volume quarter-to-quarter, movements in foreign exchange rates, particularly the Euro, and levels of advantage rebates and promotion discounts attained by our customers.

    此外,其他可能對我們毛利率結構造成正面或負面影響的因素,包括Invisalign病例量在各季之間的顯著變動、外匯匯率(尤其是歐元)的波動,以及客戶取得的advantage回饋與促銷折扣水準。

  • Turning to operating expenses. We expect some quarterly fluctuation from the Q1 levels during the year due to timing and amounts of spend relative to consumer marketing, international expansion, our R&D investments, product commercialization efforts, and significant trade show and industry events.

    接著談營運費用。由於消費者行銷、國際擴張、我們的研發投資、產品商業化推動,以及重要的貿易展與產業活動等支出在時點與金額上的差異,我們預期今年各季相較於第一季水準會有一些季度波動。

  • In summary, we believe we can continue to drive Invisalign volumes and adoption growth to build this business. We're pleased with the better than expected progress in scanner and CAD/CAM services in North America, but it's not enough to offset softness in Europe for now. Against that, with this exciting business, we remain committed to investing strategically in the same areas where you saw us deliver value in 2011.

    總結來說,我們相信我們能持續推動 Invisalign 的出貨量與採用成長,以打造這項業務。我們對北美地區掃描器與 CAD/CAM 服務的進展優於預期感到滿意,但目前仍不足以抵消歐洲的疲弱。儘管如此,面對這項令人振奮的業務,我們仍致力於在您看到我們於 2011 年創造價值的相同領域進行策略性投資。

  • To put a finer point on it, as we complete the transition out of New Jersey and bring up our new manufacturing facility in Juarez, we would expect operating margins to return to the low 20% range in the second half of 2012. With that, I'll now turn the call back over to Tom for some closing comments.

    更精確地說,隨著我們完成自新澤西的遷出並啟用位於華雷斯(Juarez)的新製造工廠,我們預期 2012 年下半年營業利益率將回到 20% 出頭的區間。接下來,我把電話交回給 Tom 做一些結語。

  • - President, CEO

    - President, CEO

  • Thanks, Ken. Well, overall, I'm very pleased with our results this past year. The strong performance is a result of good execution of our plans and strategies. I'm extremely proud of the Align team that worked so hard to deliver these results.

    謝謝你,Ken。整體而言,我對我們過去一年的成果非常滿意。這樣的強勁表現來自於我們對計畫與策略的良好執行。我為 Align 團隊的努力感到無比自豪,正是他們辛勤付出才交出這些成果。

  • We had many significant accomplishments in 2011, including the acquisition of Cadent Holdings, followed shortly after by the introduction of interoperability with Invisalign on both the iOC and iTero scanners, as well as other improvements. When we put together the strategic rationale for the Cadent acquisition, we believed that Invisalign interoperability on IOS scanners would improve utilization. While it's still very early, we're already starting to see greater Invisalign case utilization among our busier Orthodontist iOC scanner users.

    我們在 2011 年達成了許多重要里程碑,包括收購 Cadent Holdings,隨後不久便在 iOC 與 iTero 掃描器上推出與 Invisalign 的互通性,以及其他多項改進。在擬定收購 Cadent 的策略理由時,我們相信在 IOS 掃描器上實現 Invisalign 互通性將提升使用率。雖然目前仍屬非常早期,但我們已開始看到在較忙碌的矯正科醫師 iOC 掃描器使用者之中,Invisalign 病例使用率有所提升。

  • If fact, on a small base, those practices are up more than all of the Orthodontist offices by about 10%. On the GP side, Invisalign interoperability became available in the iTero scanner last month. Once it's more broadly in use across our installed base, we should get a better read on the leverage we can expect to see for Invisalign cases going forward.

    事實上,在基期較小的情況下,這些診所的成長幅度比所有矯正科診所整體高出約 10%。在一般牙科(GP)方面,Invisalign 互通性已於上個月在 iTero 掃描器上提供。一旦在我們的既有裝機基礎中更廣泛地使用,我們就能更清楚判讀未來 Invisalign 病例可望帶來的槓桿效益。

  • These early results are more positive than we expected, especially since chair-side applications aren't available yet. These early trends in this positive direction reinforces our confidence in our strategic direction, as well as our long-term growth rate targets.

    這些早期結果比我們預期更為正面,尤其是在椅旁(chair-side)應用尚未推出的情況下。這些朝正向發展的早期趨勢,進一步強化了我們對策略方向以及長期成長率目標的信心。

  • 2011 also represented the biggest evolution in the Invisalign platform's history with the rollout of Invisalign G3 internationally, launch of Invisalign G4 worldwide, as well as the introduction of Invisalign Teen and Vivera retainers in Japan. We also continued to gain share in the very important Teen Orthodontic segment in existing markets, while expanding into new geographies including China, Turkey, the Middle East, and Russia.

    2011 年也代表 Invisalign 平台史上最大幅度的演進:包括在國際市場推出 Invisalign G3、在全球推出 Invisalign G4,以及在日本導入 Invisalign Teen 與 Vivera 維持器。我們也在既有市場中持續於極為重要的青少年矯正(Teen Orthodontic)區隔提升市占,同時擴展至包括中國、土耳其、中東與俄羅斯等新地理市場。

  • Finally, we continued to make progress in establishing the Invisalign brand more strongly among dental practices and consumers alike. Invisalign has become one of the most recognizable brands in dentistry and while we're still in the early stages of our growth, we're well on the way of establishing Invisalign as one of the more valuable product franchises in dentistry or devices.

    最後,我們也持續在牙科診所與消費者之間更強化 Invisalign 品牌的建立。Invisalign 已成為牙科領域最具辨識度的品牌之一;雖然我們仍處於成長的早期階段,但我們正穩步將 Invisalign 建立為牙科或醫療器材領域中更具價值的產品系列之一。

  • All in all, one of the most outstanding years of overall performance in the Company's history and as I said before, I'm really proud the Align team that delivered these results and I'm very thankful to our customers and their patients that allowed us to be part of that treatment.

    總而言之,這是公司歷史上整體表現最出色的年度之一;如我先前所說,我非常以交出這些成果的 Align 團隊為榮,也非常感謝我們的客戶及其病患,讓我們得以參與這段治療歷程。

  • Now, we're off and running in 2012. Over the past few weeks, I've been on the road meeting with our Domestic and International teams. Our gang is optimistic about recent trends in volumes and believes we'll continue solid execution of our current plans.

    現在,我們在 2012 年已經全速啟動。過去幾週,我在外出差與我們的國內與國際團隊會面。我們的團隊對近期出貨量趨勢感到樂觀,並相信我們將持續穩健執行目前的計畫。

  • We'll also continue to focus on our top priorities and actively manage the Business while making appropriate investments to support these strategic initiatives. With all the signs of progress in this Business, I'm confident that these are the right drivers for continued growth. I'm also confident that we'll make progress in operating profitability as we go through the year and look forward to sharing that with you as the year unfolds. With that, I'll turn it back to the operator for some questions. Operator?

    我們也將持續聚焦於最優先事項,並在進行適當投資以支持這些策略性倡議的同時,積極管理業務。從這項業務的各種進展跡象來看,我有信心這些都是推動持續成長的正確動能。我也有信心我們將在今年推進營運獲利能力,並期待隨著年度進展與各位分享。接下來,我把電話交回給接線員進行提問。接線員?

  • Operator

    Operator

  • (Operator Instructions) Matt Dolan, ROTH Capital Partners.

    (接線員指示) ROTH Capital Partners 的 Matt Dolan。

  • - Analyst

    - Analyst

  • First question, Tom, maybe on the general environment it looks like Invisalign has been accelerating over the last two quarters in terms of its year-over-year growth rate, as opposed to Cadent now here in Q4 showing some softness in Europe, what are you seeing generally in your Business? Are you seeing an inflection point in the Invisalign business and Cadent is something that's Company specific, just needs to be managed through or how should we think about what we've seen in the last two quarters?

    第一個問題,Tom,關於整體環境:看起來 Invisalign 在過去兩個季度的年增率有所加速;相較之下,Cadent 在第四季在歐洲顯示出一些疲弱。你們在整體業務上普遍看到了什麼?你們是否看到 Invisalign 業務出現拐點,而 Cadent 則是公司特定、只需要管理度過的問題?或者我們應該如何看待過去兩個季度所看到的情況?

  • - President, CEO

    - President, CEO

  • Let me break those into two pieces. First of all, we're pretty excited with where our business is in general. We like our problems. The Invisalign business continues to evolve. I don't know that there's an inflection point there but we continue to make progress and I think you've seen, if we get the product evolution right and provide the right support and can create demand for these doctors, they'll take advantage of that and so over time we would expect to see continued adoption. It looks differently among Orthos and GPs but we'd expect to see that continue and then play out differently around the world.

    我把這個問題拆成兩個部分。首先,整體而言,我們對目前業務所處的位置感到相當振奮。我們喜歡我們面臨的問題。Invisalign 業務仍在持續演進。我不確定那裡是否存在所謂的拐點,但我們持續取得進展;我想你也看到了,如果我們把產品演進做對、提供正確的支援,並能為這些醫師創造需求,他們就會善加利用,因此隨著時間推移,我們預期採用度會持續提升。在矯正科與一般牙科(GP)之間的表現會有所不同,但我們預期這種趨勢會持續,並在全球各地以不同方式展開。

  • On the Cadent side, certainly this is our first year of owning this business. As Ken said, we have not been through the full cycle. Again, we started with -- it was a young Company without a lot of resources. We had to move quickly to build a sales force in North America. We believe we're getting really good traction there again, leveraging a bigger Invisalign base, we're getting great traction in North America. That itself hasn't been enough to offset softness Europe and it's too soon for us to tell whether that's secular and wide in dentistry and the economy in general but we are committed with our partner, Straumann, to re-stage that growth and I guess that's where I'd leave it.

    至於 Cadent 方面,這確實是我們擁有這項業務的第一年。如 Ken 所說,我們尚未走完整個循環。同樣地,我們接手時——那是一家年輕公司,資源不多。我們必須迅速行動,在北美建立銷售團隊。我們相信我們在那裡再次取得非常好的進展;藉由更大的 Invisalign 基礎,我們在北美獲得了很好的動能。但這本身仍不足以抵消歐洲的疲弱,而且我們現在還太早,無法判斷這是否是牙科產業與整體經濟的長期結構性問題;不過,我們承諾將與合作夥伴 Straumann 一起重新推動成長,我想我就先說到這裡。

  • - Analyst

    - Analyst

  • Okay. Then Ken, maybe on your operating margin commentary, we've gone through a couple of quarters here where you've had similar thoughts and now the margin actually comes in, in the low to mid 20% depending on a GAAP or non-GAAP basis. Just give us the outlook into 2012. Are these added expenses year-over-year or is most of the margin impact due to maybe a lower gross margin and just trying to weigh that with some of the new things we have like legal and several of the marketing programs, et cetera? So just help us understand the moving parts there?

    好的。那 Ken,關於你對營業利益率的評論,我們已經歷了幾個季度,你們有類似的看法,而現在實際的利益率落在 20% 出頭到中段,視 GAAP 或 non-GAAP 口徑而定。請談談 2012 年的展望。這些新增費用是年對年增加的嗎?還是大部分的利益率影響來自於毛利率較低?我想把這些與一些新項目(例如法律費用與多項行銷計畫等)一起衡量。所以請協助我們理解其中的變動因素?

  • - VP, CFO

    - VP, CFO

  • Sure, Matt. I guess I'll start with gross margin which is the comment I made on the call here, which is that we think we're going to continue to run at the lower end of the range, maybe slightly below. That's going to certainly be dependent on Invisalign volumes as we go over the quarters here. But once we complete that transition, we should start seeing margins move up on the scanner side of the business in particular, and then also as we continue to fill out the new factory with volume as we move through 2013, we'll see that start to improve as well. On the operating expense side of the business, what we see with relation to the comment on employee compensation and benefits-related programs, each year in the quarter-one timeframe, we go through annual review cycles, salary adjustments and those types of things and benefits programs that people get signed up for in the quarter-four timeframe -- about halfway through the quarter and that starts taking effect in the New Year as well.

    當然,Matt。我想我先從毛利率談起,也就是我在這通電話裡提到的評論:我們認為毛利率將會持續落在區間的低端,甚至可能略低一些。這當然會取決於我們在接下來幾個季度的 Invisalign 出貨量。但一旦我們完成那項轉換,我們應該會開始看到,特別是在掃描器業務端的毛利率往上走;此外,隨著我們在 2013 年推進、以更多產量持續把新工廠的產能填滿,我們也會看到毛利率開始改善。在營運費用方面,針對我提到的員工薪酬與福利相關計畫,每年在第一季期間,我們都會進行年度評核循環、薪資調整等事項,以及員工在第四季期間(大約在該季中段)會完成加入的福利計畫——這些也會在新年度開始生效。

  • So those are a bit of step up in spending on a year-over-year basis and then in the consumer marketing area, we're off quite a bit in quarter four with the holiday seasons, off air. When you come into quarter one here we're actually stepping up our advertising. We typically do in quarter one off of quarter four.

    因此,這些在支出上會呈現一些年對年的階梯式上升;另外在消費者行銷方面,第四季因為假期季節,我們的投放明顯減少、停播。進入第一季後,我們其實會提高廣告投放。我們通常在第一季相較第四季會這麼做。

  • I guess the other comment I would make on media spending is, this past year we stepped it up in quarter two and quarter three with the Teen season and I would expect this year we do something very similar to that. Probably the only difference being working around the Olympics a bit. We'll probably be a little heavier on spending in quarter two in relation to some of the media and maybe more so than we had in the past. But we'll be looking at that to drive Teenage case starts as we move through the summer months.

    我想我對媒體支出的另一個評論是:去年我們在第二季與第三季配合青少年季(Teen season)加大了投放,我預期今年也會做非常類似的安排。可能唯一的差異是需要稍微配合奧運檔期。相較於過去,我們可能會在第二季針對部分媒體投入更高一些,甚至比以往更重。但我們會以此來推動青少年病例啟動數(Teenage case starts),一路延伸到夏季月份。

  • - Analyst

    - Analyst

  • Just to clarify, sorry, if we hold gross margin constant for 2012 are you seeing leverage in the operating expense line or are these -- some of those examples you went through, above and beyond the growth of what we should anticipate on the top line?

    只是想釐清一下,抱歉,如果我們在 2012 年把毛利率維持不變,你們是否會在營運費用項目看到槓桿效益?還是說——你剛剛舉的那些例子,是超出我們應該預期的營收成長所帶來的增幅?

  • - VP, CFO

    - VP, CFO

  • I think -- if you step back from it all and you look at top-line growth on Invisalign on a quarterly basis here and you look at where FX rates were a year ago even or you look at where they were last quarter to this quarter and what we see now coming in -- last quarter to this quarter being Q3 to Q4 and where they are coming into quarter one there certainly is an impact on top line which is having some impacts on gross margin. Now as far as -- yes, we think we'll get some leverage in our spending, as Tom mentioned. We're more efficient and effective in our advertising and lead generation. We'll be feathering in a few headcount in the North America sales team on a smallish basis to look at supporting the continued growth. But I believe as we move through the year and you see top line continuing to grow, we'll start seeing the leverage again in the operating expense line.

    我想——如果你退一步看整體,觀察 Invisalign 的季度營收成長,再看看匯率(FX)相較一年前、甚至相較上一季到這一季的變化,以及我們現在看到進入第一季的水準——上一季到這一季指的是第三季到第四季——匯率確實會對營收端造成影響,而這也對毛利率帶來一些影響。至於——是的,我們認為在支出上會有一些槓桿效益,如 Tom 所提。我們在廣告與名單開發(lead generation)方面更有效率、也更有效果。我們會在北美銷售團隊以小幅度逐步增加一些人力編制,以支援持續成長。但我相信,隨著我們在今年推進、你看到營收持續成長,我們會再次開始在營運費用線上看到槓桿效益。

  • - Analyst

    - Analyst

  • Okay, thanks.

    好的,謝謝。

  • Operator

    Operator

  • John Kreger, William Blair.

    John Kreger,William Blair。

  • - Analyst

    - Analyst

  • Just to come back to the situation around Europe. From your comments does it seem like your Invisalign shipments have really not been impacted yet in Europe but the scanner shipments have? And if that's true, why do you think that you're seeing the difference?

    我想再回到歐洲的情況。從你們的評論來看,是否意味著你們在歐洲的 Invisalign 出貨其實尚未受到影響,但掃描器出貨已經受到影響?如果是這樣,你們認為為什麼會看到這種差異?

  • - President, CEO

    - President, CEO

  • Well, this is Tom here, John. The businesses are really in two very different places. With our partner -- literally Cadent was just getting going with a relationship, with a very new technology and kind of getting early adopters going. With Invisalign, we've been at it for the better part of ten years in Europe. In the last several years have made substantial progress in gaining adoption support, et cetera. So, I think you could take a snap shot and these are technologies and products -- Invisalign's maybe in the second inning, third inning and our scanner business is literally -- they're just still warming up. If I come back to what's going on there, difficult for us at this point to sort out large secular trends in dentistry given the very early penetration of scanner technology from general economy to capital equipment purchasing, there are some signs that dentists and specialists are being conservative about capital spending and a variety of other things.

    John,我是 Tom。這兩個業務其實處在非常不同的階段。就我們的合作夥伴而言——嚴格說 Cadent 才剛開始建立合作關係,技術非常新,且仍在推動早期採用者。至於 Invisalign,我們在歐洲已經耕耘了將近十年。過去幾年在提升採用度、支援等方面取得了實質進展。所以,如果你做一個快照來看,這些技術與產品——Invisalign 可能已經在第二局、第三局,而我們的掃描器業務基本上——還在熱身階段。回到當地正在發生的事,鑑於掃描器技術仍處於非常早期的滲透階段,我們目前很難把牙科領域的長期結構性趨勢,與一般經濟環境對資本設備採購的影響清楚區分;但確實有一些跡象顯示,牙醫與專科醫師在資本支出上較為保守,以及其他各種因素。

  • So, we choose to believe that once we get ourselves organized properly and with the right product programs and support, we can even drive into a difficult economy and we certainly see that with Invisalign. But again we haven't even had the scanner business for a full business cycle yet and so, again, I'm going to lean back on what some of the larger dental companies are reporting around what is going on in Europe. For the Invisalign case, we're pushing through that, although we've adjusted our game and we're even back to improving in the UK again. Several years ago when Germany was down, we invested in coverage and approach. So we've re-staged growth in countries like Germany and France, even in this environment. So, it may be a very long answer to your short question, we believe it's possible to get that going again, but I don't know that I would say we have complete closure on all of the issues behind re-staging growth on the scanner side. But we're working on it.

    因此,我們選擇相信,一旦我們把組織、產品方案與支援都到位,即使在艱困的經濟環境中也能推動成長,而我們在 Invisalign 上確實看到這點。但同樣地,我們的掃描器業務甚至還沒有經歷完整的一個景氣循環,因此我仍會參考一些大型牙科公司對歐洲現況的揭露。就 Invisalign 病例而言,我們正在推進,雖然我們調整了打法,而且在英國也再次回到改善的軌道。幾年前德國下滑時,我們加大了覆蓋與作法上的投資。因此,即使在目前的環境下,我們也在德國、法國等國家重新拉升成長。所以,這可能是對你簡短問題的一個很長的回答:我們相信有可能讓它再次動起來,但我不會說我們已經完全釐清掃描器端重新拉升成長背後的所有問題。但我們正在努力。

  • - Analyst

    - Analyst

  • That's helpful, thanks. A quick follow-up. Are you seeing any change in the competitive landscape for scanners and might that explain any of this?

    這很有幫助,謝謝。我再快速追問一下。你們是否看到掃描器的競爭態勢有任何變化,而這是否可能解釋其中一部分原因?

  • - President, CEO

    - President, CEO

  • Yes, well short answer is no. There's a lot of people working on scanners. There's very few releases and launches. There's not volume being lost to other people. This is just very early in the evolution of technology, so there's a lot of noise. Don't sense that that's the issue why people are not buying or they're buying more slowly. And again, capital equipment purchasing is very sensitive to that. But there's no -- as I said there's no new competitors, no x-factors that have worked into that market lately. Anything that was going to be coming out in market was discussed during IDS going on a year ago and most of those launches have not happened at scale yet. So, again, I would say it's really more of a market dynamic than it is a competitive dynamic at this point.

    是的,簡短答案是沒有。有很多人在做掃描器。但真正的發表與上市很少。也沒有看到量被其他人搶走。這只是技術演進非常早期的階段,所以雜訊很多。我不覺得這是人們不買、或買得更慢的原因。而且,資本設備採購對這些因素非常敏感。但沒有——如我所說,近期沒有新的競爭者、也沒有任何 X 因素進入這個市場。任何原本預期會推出到市場的產品,在大約一年前的 IDS 展會期間就已經被討論過,而其中多數上市至今仍未達到規模化。所以,我會說目前更像是市場動態,而不是競爭動態。

  • - Analyst

    - Analyst

  • Great, thanks very much.

    很好,非常感謝。

  • Operator

    Operator

  • Brandon Couillard, Jefferies.

    Brandon Couillard,Jefferies。

  • - Analyst

    - Analyst

  • Tom and/or Ken, if we look back last year when you announced the Cadent transaction, I believe you indicated you expected the deal to be accretive to non-GAAP EPS in 2012 and understanding some of the restructuring actions won't be completed until the second half, but do you still feel comfortable with that view or do you at least expect Cadent to achieve breakeven status in 2012? Then as a corollary, any chance you would be willing to give us the Cadent operating income or loss in the fourth quarter?

    Tom 和/或 Ken,如果我們回顧去年你們宣布 Cadent 交易時,我記得你們表示預期該交易在 2012 年會對非 GAAP 每股盈餘(EPS)具增益(accretive);我理解部分重整措施要到下半年才會完成,但你們現在仍對這個看法感到有把握嗎?或者你們至少預期 Cadent 在 2012 年能達到損益兩平?另外作為延伸問題,你們是否願意提供 Cadent 在第四季的營業利益或損失?

  • - VP, CFO

    - VP, CFO

  • Yes, Brandon, this is Ken I'll start it and maybe Tom can add to it. So from a financial point of view and you look at the business and where we are right now, as we said we're going to have restate some of the growth in Europe here with our business partner, and that will probably take a little bit of time here, but overall we have been investing pretty heavily in the Cadent business in the near-term here to bring salespeople on board in various marketing programs and get the business moving. We've had investments in relation to having interoperability with the iOC and iTero scanners and as Tom mentioned moving towards applications in chair-side. So we're investing on the R&D side of the business. We think as we continue to re-stage that growth we'll start moving towards a level of profitability that's greater than what it is today.

    是的,Brandon,我是 Ken,我先來回答,或許 Tom 也可以補充。從財務角度來看,檢視我們的業務以及目前所處的位置,如同我們所說,我們將與業務夥伴在歐洲這邊重新調整部分成長布局,這可能需要一些時間;但整體而言,短期內我們一直在 Cadent 業務上投入相當多資源,包括招募各類行銷方案的業務人員,推動業務運轉。我們也在與 iOC 與 iTero 掃描器互通性方面進行投資,並如 Tom 所提到,朝向椅旁(chair-side)應用發展。因此我們正在業務的研發端投入。我們認為,隨著我們持續重新布局這項成長,我們將開始朝向比目前更高的獲利水準邁進。

  • With that, I will say we do not track inside the Company specifically, operating margins for the scanner side of the business. Though from a functional basis, all organizations, marketing, R&D, sales, et cetera is fully integrated into the Invisalign business which is why on a go-forward basis we'll be tracking gross margins and reporting them out to you. But below that because there's a lot of cross functional work that goes on across both sides of the business, we're not going to be tracking that on a go-forward basis. What I would say is that it's probably going to take us a little longer to see the acquisition become accretive to us, but I think we're making some great strides in the short-term here, over the last six months and getting things in place to do that.

    另外我要說的是,我們在公司內部並未針對掃描器業務特別追蹤其營業利益率。不過從職能面來看,所有組織—行銷、研發、銷售等等—都已完全整合進 Invisalign 業務之中,因此未來我們會追蹤毛利率並對各位揭露。但在毛利率以下,由於業務兩端之間存在大量跨職能協作,未來我們不會再以同樣方式追蹤。我想說的是,這項收購要對我們產生增益(accretive)可能還需要更長時間,但我認為在短期內、過去六個月,我們已取得很大進展,並把相關事項逐步到位以達成這點。

  • - President, CEO

    - President, CEO

  • Brandon, if I could bolt onto that a little bit. If we choose to, because we thought that was the best way to deliver economic value to our shareholders, we could have operated this in a more traditional stand-alone basis and we could have exactly done what we originally described. When we really got into detail in the integration planning, we saw enormous opportunities for better leverage in the business to drive medium to long-term growth much higher. To drive medium to long-term margins higher on products in the services stream and to take advantage of what's a pretty rapidly evolving -- we'll call it new digital restorative -- I hate to use the word, but I'll use it ecosystem. So we moved very quickly to fully integrate this business in and actually to accelerate some spending. A really good example here is, we aren't just moving the New Jersey facility to Juarez for a cost reduction. In fact, the principal initial driver was we felt we could really scale that business. But to scale it in New Jersey, to add a lot of new capital, potentially have to move it and to do so at a quality and level of kind of digital control that we wanted, that we had in Juarez or Costa Rica, we made the choice to invest in accelerating that program which initially we hadn't planned on doing for maybe years or more.

    Brandon,如果可以的話我再補充一點。如果我們選擇那樣做,因為我們原本認為那是為股東創造經濟價值的最佳方式,我們本可以用更傳統的獨立(stand-alone)方式來營運,也可以完全照我們最初描述的方式去做。但當我們真正深入整合規劃的細節時,我們看到在業務上有巨大的槓桿機會,能把中長期成長推得更高。也能把產品與服務收入流(services stream)的中長期毛利率推得更高,並把握一個正在快速演進的—我們姑且稱之為新的數位修復(digital restorative)—我不太想用這個詞,但我還是用—生態系(ecosystem)。因此我們非常快速地把這項業務完全整合進來,並且實際上加速了部分支出。一個很好的例子是:我們不只是為了降低成本而把新澤西的廠房搬到華雷斯(Juarez)。事實上,最初的主要驅動因素是我們認為可以真正擴大該業務規模。但若要在新澤西擴產,就得增加大量新資本投入,甚至可能仍需搬遷;而要達到我們想要的品質與數位化控制水準(我們在華雷斯或哥斯大黎加已具備),我們選擇投資並加速該計畫,而這在一開始我們可能原本並未打算在未來幾年內就做。

  • So that's an example of where we can scale better, deliver better quality to customers, enable some fully new kinds of products and get $1 million a quarter or better gross margin improvement out of the business once completed. So that puts a little more pressure in the near-term but as we look even a mid-term outlook for this business we believe -- A, we can drive better gross margins on the product and services mix, and then over the long-term substantially better; and then B, we can support scalability dramatically better. So that investment is playing out all across from sales and marketing side touching customers, all the way through the technology and the IT infrastructure to the manufacturing base and we're just working very hard to completely integrate that into what we do here. So those were choices we made once we got in and really understood the business in a more detailed way and elected to make those investments. So it is a little bit of more near-term pain, but we believe the pay backs on those are outstanding. I think in general, if you look at our track record for Invisalign and the choices we've made around optimizing manufacturing management and flow, in general we've shown we know how to do that well.

    因此這是一個例子,說明我們如何能更好地擴大規模、為客戶提供更好的品質、促成一些全新的產品類型,並在完成後讓該業務每季帶來約 100 萬美元或更高的毛利改善。這在短期內會帶來一些壓力,但即便從中期展望來看,我們相信—A,我們可以在產品與服務組合上推動更好的毛利率,長期則可大幅提升;B,我們也能以顯著更好的方式支援可擴展性。因此這項投資正全面展開,從接觸客戶的銷售與行銷端,一路延伸到技術與 IT 基礎設施,再到製造基地;我們正非常努力把它完全整合進我們在這裡所做的一切。這些都是我們在進入後、以更細緻方式真正理解該業務後所做的選擇,並決定進行這些投資。所以短期會有多一些痛苦,但我們相信其回報非常出色。整體而言,如果你看我們在 Invisalign 的過往紀錄,以及我們在最佳化製造管理與流程方面所做的選擇,一般來說我們已證明我們很擅長把這件事做好。

  • - Analyst

    - Analyst

  • Okay, that's helpful and then, Ken, what was the impact of FX on revenue growth in the fourth quarter and the full year? And then any chance you could give us the anticipated revenue impact that's embedded in your first-quarter revenue guidance?

    好的,這很有幫助。接著,Ken,第四季與全年營收成長中,匯率(FX)的影響是多少?另外,你能否提供一下,你們第一季營收指引中所內含的預期匯率對營收影響?

  • - VP, CFO

    - VP, CFO

  • Let me make a comment about -- start with the fourth quarter here. So coming into the quarter in Q3 FX rates were around the Euro were averaging around $1.40, $1.42. This past quarter they averaged around $1.35. So if you look at our international revenues and you do the calculation, you'll come up with roughly about $1.5 million impact or so, $1.7 million impact on revenues on a quarter-over-quarter basis. In relation to our quarter-one guidance, we have our view of where exchange rates are currently and where they've been over the past month or so, down as low as $1.27ish and maybe even a little bit lower than that and right now bouncing around $1.31. So we think there's going to be some quarterly impact on a quarter-over-quarter basis. I don't want to put a finer point on that, but that's kind of how we're reviewing things. We have our own view of where we think exchange rates are going to be and the flow of product for the quarter impacts. On a year-over-year basis, if you think about where exchange rates were in 2010, they were anywhere from $1.35, $1.40ish range and they stayed there early this year in 2011 for the first couple of quarters and then over the last part of the year they've come down dramatically. It's several million dollars of impact on the full-year basis.

    我先從第四季開始說明。在第三季進入第四季時,歐元相關的匯率平均約在 1.40 美元、1.42 美元左右。而在剛過去的這一季,平均約在 1.35 美元。因此如果你看我們的國際營收並做計算,按季(quarter-over-quarter)來看,對營收的影響大約是 150 萬美元左右,或約 170 萬美元左右。至於我們第一季指引,我們是依據目前匯率水準以及過去一個月左右的走勢來看,最低曾到約 1.27 美元左右,甚至可能更低一些,而目前大約在 1.31 美元附近波動。因此我們認為按季來看會有一些影響。我不想把數字說得太精確,但我們大致就是用這樣的方式在檢視。我們對匯率走勢有自己的看法,也會考量本季產品出貨節奏對影響的反映。若以年對年(year-over-year)來看,回想 2010 年的匯率大約在 1.35 美元到 1.40 美元左右,2011 年前兩季也大致維持在那個區間,但在今年後半段已大幅下滑。以全年來看,影響是數百萬美元等級。

  • - Analyst

    - Analyst

  • Okay, thank you.

    好的,謝謝。

  • Operator

    Operator

  • Jose Haresco, JMP Securities.

    Jose Haresco,JMP Securities。

  • - Analyst

    - Analyst

  • Just not to beat a dead horse here, but on the gross margin side, something you mentioned. It looks like we're splitting the difference between FX and some of these rebates. One, can you remind us again of the Advantage Rebate Programs, how that actually plays out, the discounts to the docs. What kind of an ASP should we be modeling for -- call it the first half or so and are some of your operating margin comments abut it hitting in the low 20%s at least predicated partially in the assumption that ASPs climb back up in the second half?

    不是要一直重複問同一件事,但在毛利率方面,你提到的一點。看起來我們是在匯率(FX)與其中一些回饋(rebates)之間取了折衷。第一,你能再提醒我們一次 Advantage 回饋計畫(Advantage Rebate Programs)是如何運作的嗎?也就是對醫師(docs)的折扣是怎麼反映的。就 ASP(平均售價)而言,若以—姑且說上半年左右—我們應該建模到什麼水準?另外,你提到營業利益率至少落在 20% 出頭的那些評論,是否部分是建立在 ASP 於下半年回升的假設之上?

  • - VP, CFO

    - VP, CFO

  • Sure, Jose, this is Ken. In relation to the Advantage program, the way it works is if a doctor does 12 or more cases a quarter they start participating in the program as far as discounts are concerned. The highest level of discount a doctor can get is up to $700 off your cases. So effectively brings their price on a full case from roughly $1,500 down to roughly $800. It tiers from there. Anyway -- a doctor going from 12 case then 24 cases and it moves up from there. So at 12 cases they get $500. At 24 cases or more they get $600 and then 36 or more in a quarter they get $700 off. What we've been seeing here in the past several quarters as we've been driving utilization here in the business with G3, G4 and other advertising that we've been doing, et cetera, doctors feeling more confident in using product, we've seen doctors start to move up several quarters ago now in the tiers themselves and more doctors attaining rebates, where in fact this past quarter was a record number of doctors that attained rebates from us over the quarter-four timeframe. Our anticipation as we continue to drive Invisalign volumes will continue -- more doctors will continue to participate in that Advantage program. Now with that said, that it's a very good program for us. It's -- the economics around that particular program are very favorable to Align Technology in relation to driving incremental volume. So as I see rebates increasing, I look at that as a good thing because we're getting more doctors doing more cases on a year-over-year basis.

    當然,Jose,我是 Ken。關於 Advantage 計畫,它的運作方式是:如果一位醫師每季做 12 個或以上的病例,就會開始參與該計畫並享有折扣。醫師可獲得的最高折扣為每個病例最高可折 $700。因此,完整病例的價格可有效地從約 $1,500 降至約 $800。折扣是分級的。總之——醫師從每季 12 個病例到 24 個病例,之後會再往上提升。所以在 12 個病例時可得 $500。在 24 個或以上可得 $600,而每季 36 個或以上則可得 $700 折抵。我們在過去幾季看到,隨著我們透過 G3、G4 以及其他廣告等方式推動業務使用率、醫師對產品使用更有信心,醫師在幾季前就開始在分級中往上移動,更多醫師達到可獲得回饋金的門檻;事實上,本季在第四季期間達到回饋金的醫師數量創下紀錄。我們預期,隨著我們持續推動 Invisalign 的出貨量,將會有更多醫師持續參與 Advantage 計畫。話雖如此,這對我們而言是一個非常好的計畫。就推動增量出貨量而言,該計畫的經濟效益對 Align Technology 非常有利。因此當我看到回饋金增加時,我會把它視為好事,因為這代表有更多醫師在年對年基礎上做更多病例。

  • - President, CEO

    - President, CEO

  • Unpack that from FX, the second part of the question.

    把匯率(FX)的影響拆開來看,這是問題的第二部分。

  • - VP, CFO

    - VP, CFO

  • Yes, I was just going to move on to that. So, from an FX point of view as I said a few moments ago and you look at our predominantly all of our business internationally being in core Europe, we get impacted on a quarter-over-quarter basis, as those rates are moving around. And more recently they've moved around pretty quickly here in the past quarter or so, so I had negative impact on our overall margins in the business. And as we move through the year, we have our views of where exchange rates are going to be as we built our plans out, but as we move through the year, the operating margin expansion that I referred to is really going to come from driving top-line revenues in the business, increasing Invisalign volumes, taking shared share and the North American scanner business is going very well for us and we think that will continue to go well.

    是的,我正要接著談那一點。所以,從匯率(FX)的角度來看,正如我剛才提到的,考量到我們幾乎所有的國際業務主要都在歐洲核心地區,當匯率波動時,我們會在季對季的基礎上受到影響。而最近這些匯率在過去一季左右波動得相當快,因此對我們整體利潤率造成了負面影響。隨著我們進入今年,我們在制定計畫時對匯率走勢有自己的看法,但在年度推進過程中,我先前提到的營業利益率擴張,主要將來自推動業務的營收成長、提高 Invisalign 出貨量、提升市占;同時北美的掃描器業務對我們而言表現非常好,我們認為這將會持續。

  • We've only gotten the sales team on board from the scanner side of the business just recently. So we haven't even really seen the leverage from the sales team prospective. We've seen it through events and other trade show events that we've been at, as Tom was referring to on the call. And over the next year as we get more traction with the sales team on the ground, I think we'll start seeing some effects of that as we move through the second half of the year. It's going to take them a quarter or two to really come up to speed and as volumes increase, as we move through the year we'll start seeing that leverage in the business.

    我們在掃描器業務這一端,最近才剛把銷售團隊到位。因此,從銷售團隊的角度來看,我們其實還沒有真正看到槓桿效益。我們已經在活動以及其他我們參與的展會上看到一些效果,正如 Tom 在電話會議中提到的。而在接下來一年,隨著我們的第一線銷售團隊取得更多進展,我認為當我們進入下半年時會開始看到一些影響。他們需要一到兩季才能真正上手;隨著年度推進、出貨量增加,我們將開始看到這項業務的槓桿效益。

  • - Analyst

    - Analyst

  • Can you share with us what percentage of your customer base right now in either channel is taking advantage of the Advantage Rebate Program. You said it was -- you said you had the highest percentage of docs you've ever seen using this rebate. But if you look at your total worldwide blend of ASPs. It really didn't decline all that much. So is there something else? There seems to be a disconnect there, because you're only off by like $25 on your ASP. The reductions you talk about are really quite drastic.

    你們能否分享一下,目前在任一通路中,你們的客戶基礎有多少百分比正在使用 Advantage 回饋計畫?你說——你說你們看到使用這項回饋的醫師比例是史上最高。但如果看你們全球混合的 ASP(平均銷售單價)。其實並沒有下降太多。所以是否還有其他因素?這裡似乎有點不一致,因為你們的 ASP 只下降了大約 $25。你們談到的降幅其實相當劇烈。

  • - VP, CFO

    - VP, CFO

  • Again, the Advantage Rebate Program itself there was a record number of doctors, but it's not the entire base of doctors that participate in the program. (Multiple speakers) Remember from an utilization point of view, they have to be doing 12 cases or more a quarter to participate in the program. Once they start getting that volume. So it's a smaller percentage of the doctors. As far as GPs and Orthos, it's across both channels where doctors are participating. You can imagine on the Ortho side of the business with their utilization rates being a little higher. Those doctors are earning probably a little more rebate. We have a fair amount of GPs that are earning some very nice rebates as well.

    再說一次,Advantage 回饋計畫本身確實有創紀錄數量的醫師參與,但並不是所有醫師都參與該計畫。(多位講者) 請記得,從使用率的角度來看,他們必須每季做 12 個或以上的病例才能參與該計畫。也就是要先達到那個出貨量。因此參與的醫師占比相對較小。至於一般牙醫(GPs)與矯正專科(Orthos),兩個通路都有醫師參與。你可以想像,在矯正端因為使用率稍高。那些醫師可能會拿到稍多一些的回饋。我們也有相當多的一般牙醫同樣拿到非常不錯的回饋。

  • - Analyst

    - Analyst

  • Okay. Just last question is where do you guys think are you in terms of penetrating the Teen market in terms of percentage of total volume in 2011? Where do you think [that's going to be year end]?

    好的。最後一個問題是,就 2011 年總出貨量的占比而言,你們認為自己在青少年(Teen)市場的滲透率大概到什麼程度?你們覺得[到年底會是多少]?

  • - President, CEO

    - President, CEO

  • Can you ask that again, Jose?

    Jose,你可以再問一次嗎?

  • - Analyst

    - Analyst

  • Sure. What percentage of the total US Teen cases do you guys think you did in all of 2011?

    當然。你們認為在 2011 年全年,你們做了美國青少年病例總量的多少百分比?

  • - President, CEO

    - President, CEO

  • I think the first question is we don't see the whole market so we're not the best arbiter. But with that said, we think the numbers we generally describe in terms of market size are reasonably accurate and we think what we've seen lately from a variety of sources is -- implies kind of 3% to 4% total growth at least in the segments that matter for us. So, I think with the numbers we've used before for market size you could add those and then take our numbers -- it implies we're gaining share pretty quickly and it probably understates the category expansion we're delivering. But I think if you go look at Teen for example, we're still a very small low-single digits in terms of total penetration into Teen. We've got a lot of head room there and if you get into Europe and places like that, it's an order of magnitude less.

    我想第一點是,我們看不到整個市場,所以我們不是最好的評判者。但即便如此,我們認為我們一般用來描述市場規模的數字相當合理,而且我們最近從各種來源看到的情況——至少在對我們重要的細分市場——暗示總體成長大約在 3% 到 4% 左右。所以,我認為以我們先前使用的市場規模數字來看,你可以把那些加總起來再對照我們的數字——這意味著我們的市占提升得相當快,而且可能低估了我們所帶動的品類擴張。但我認為如果你去看青少年(Teen)例如,我們在青少年總滲透率方面仍然非常低,只有個位數低段。我們還有很大的成長空間;而如果你看歐洲等地,滲透率還要再低一個數量級。

  • - Analyst

    - Analyst

  • Okay, thanks guys.

    好的,謝謝各位。

  • Operator

    Operator

  • Steve Beuchaw, Morgan Stanley Smith Barney.

    Steve Beuchaw,Morgan Stanley Smith Barney。

  • - Analyst

    - Analyst

  • This is Jon Demchick in for Steve. Tom, you took a bit of a more active role in the marketing department during the fourth quarter, I believe. Can you tell us why you did that and what you were looking to accomplish with the changes there?

    我是 Jon Demchick,代替 Steve。Tom,我相信你在第四季在行銷部門扮演了更積極的角色。你能告訴我們你為什麼這麼做,以及你希望透過那裡的變動達成什麼目標嗎?

  • - President, CEO

    - President, CEO

  • Well, I guess that's why things aren't working so well, huh? I -- actually I'm only involved, other than my normal mode -- we look at marketing as everybody in the Company is involved. We all own the customer. We all own evolution of the product and we all own execution of the game plan which includes marketing and other things in it. So at some level absolutely nothing's changed. At another level I actually -- my level of involvement was to place Tim Mack in charge in December, a very, very experienced technology guy and GM and long-term dental expert, restorative dentistry and elsewhere. He's doing a terrific job for us, while we have a search going on for part of the role. The second part of the role, we have a very, very good consumer team that is doing a terrific job and I'm just trying to ask enough questions and stay out of the their way and so that's my level of involvement.

    嗯,我想這就是為什麼事情運作得不太好,對吧?我——其實除了我平常的模式之外,我只是參與其中;我們看待行銷的方式是,公司裡每個人都參與其中。我們都對客戶負責。我們都對產品的演進負責,也都對包含行銷在內的整體計畫執行負責。所以在某個層面上,絕對沒有任何改變。在另一個層面上,我實際上的參與是:在 12 月任命 Tim Mack 負責,他是一位非常、非常有經驗的科技人士與總經理,並且是長期的牙科專家,涵蓋修復牙科等領域。在我們針對部分職責進行招募的同時,他為我們做得非常出色。至於職責的第二部分,我們有一個非常、非常優秀的消費者團隊,表現也非常出色;我只是試著多問一些問題、不要妨礙他們,所以這就是我參與的程度。

  • - Analyst

    - Analyst

  • Okay, thank you, very, very helpful.

    好的,謝謝你,非常、非常有幫助。

  • - President, CEO

    - President, CEO

  • No problem.

    不客氣。

  • - Analyst

    - Analyst

  • Tom, a few weeks ago at an investor presentation you indicated that you see the lower end of the market, say the five tray market as growing the fastest within the clear aligner market. Could you put some numbers to that? How big is that market? How fast is it growing? Why move into that segment rather than pushing more aggressively toward the more challenging cases?

    Tom,幾週前在一場投資人簡報中你提到,你認為市場的低端——例如五副牙套的市場——在透明矯正器市場中成長最快。你能用一些數字來量化嗎?那個市場有多大?成長速度有多快?為什麼要進入那個區隔,而不是更積極地推進到更具挑戰性的病例?

  • - President, CEO

    - President, CEO

  • Well, first of all we are. The first thing is, we are going both ends and our goal was to be better complete coverage from end to end so to speak. We have been -- all of our efforts over the last five years roughly in terms of science and technology and evolving the product have been targeted at getting us those complex cases. Our goal some day is why would anybody want to have braces if we could do everything braces could do, better? That's the goal. That's still our goal. At the same time, we've seen a number of customers ask us, there's still patients out there that, gee for what Invisalign Express 10 at the time cost and for what they have to charge there's still some simple relapse cases. More and more where we see the growth coming from is, to a lesser extent the OEM companies like ourselves, the Danaher's or others with a low-end product like Simpli5 or whatever; to a greater extent it's the hundreds and hundreds of dental labs that are making at $100 a liner or something. These five or six stages of trays and then when patients wear them they report they aren't as satisfied with them. The doctors don't know quite when they're going to be finished and they have to talk to the patient about, what will I be able to get you to? What level of correction and can I treat that chief complaint. That gap or that little bit of crowding. We figured why not get after this as we now have all of the initiatives in hand. All the initiatives in hand with getting after more complex cases, why not bring the same leverage down at the low end where our value proposition can be better for a very cost effective approach and the feedback we've gotten since releasing it has been very, very positive. So, that's why to do it. It's just to be a much more complete competitor across the line of clear liners.

    嗯,首先,我們確實也在做。第一點是,我們兩端都在做,我們的目標是從頭到尾提供更完整的覆蓋,這麼說吧。過去大約五年,我們在科學與技術以及產品演進方面的所有努力,都是為了讓我們能處理那些複雜病例。我們某一天的目標是:如果我們能把傳統牙套能做的事都做得到,而且做得更好,為什麼還會有人想戴牙套?這就是目標。這仍然是我們的目標。同時,我們也看到不少客戶跟我們說,市場上仍有一些患者——嗯,以當時 Invisalign Express 10 的成本,以及醫師必須收取的費用來看——仍然存在一些簡單的復發病例。我們看到成長來源愈來愈多的是:較小一部分來自像我們這樣的 OEM 公司、Danaher 或其他推出像 Simpli5 之類的低端產品;更大一部分則來自數以百計的牙科實驗室,它們可能以每副矯正器 100 美元左右的價格在製作。這些五或六個階段的牙套,患者戴了之後回報說滿意度不高。醫師也不太確定何時會結束,還得跟患者溝通:我能把你矯正到什麼程度?能達到什麼樣的矯正水準,能不能解決主要訴求。例如那個縫隙或那一點點擁擠。我們想,既然我們現在已經把所有針對更複雜病例的各項計畫都掌握在手,為什麼不也來做這一塊?既然我們已經掌握了攻克更複雜病例的所有計畫,為什麼不把同樣的槓桿帶到低端市場,在那裡以非常具成本效益的方式,讓我們的價值主張更好;而且自從我們推出後收到的回饋非常、非常正面。所以,這就是我們要做的原因。就是要在透明矯正器的整條產品線上,成為更完整的競爭者。

  • Operator

    Operator

  • Jonathan Block, SunTrust.

    Jonathan Block,SunTrust。

  • - Analyst

    - Analyst

  • Maybe the first one is just if you can talk to -- Tom, you discussed a lot more in the cases that are being submitted digitally and that's obviously a benefit of the Cadent acquisition. If you can talk to what you're seeing from those accounts in terms of their overall utilization, where were they prior to submitting with Cadent and where have they gone after submitting a completely digital case?

    也許第一個問題是,如果你能談談——Tom,你提到有更多病例是以數位方式提交的,這顯然是收購 Cadent 帶來的好處。你能談談你從那些客戶端看到的整體使用情況嗎?他們在使用 Cadent 提交之前是什麼狀況,而在提交完全數位化病例之後又變成什麼狀況?

  • - President, CEO

    - President, CEO

  • Sure. The two qualifiers are put around this is, number one, this is mostly Orthodontists because we're just now getting bit of a read given iTero interoperability. So I'll remind you that it was just Orthodontist, started back, middle of May when we released interoperability on the iOC scanner. Secondly in general, the Orthodontists that ran out and bought scanners were in general higher volume. Not maybe off of the top of that map, but higher volume than our median Orthos. So the short answer inside that is they have, in general -- after you adjust for other factors, market growth, G3, everything else that's happening, they have grown utilization faster up to 10% than the other doctors. So, they report after minimal startup -- patients a lot happier, staff happier, fewer re-impression, bring the patient back in for rejected impressions, aligner fit better et cetera, et cetera, et cetera on virtually every measure. Significant enough that it really matters to us and it really matters to the patient.

    當然。這裡有兩個前提:第一,這主要是矯正專科醫師,因為我們才剛開始因 iTero 互通性而取得一些觀察。所以我提醒一下,這原本只針對矯正專科醫師,大約從我們在 iOC 掃描器上釋出互通性的 5 月中旬開始。第二,一般來說,急著去買掃描器的矯正專科醫師,通常本來就是較高量的使用者。也許不是那張分布圖最頂端的那一群,但比我們矯正專科醫師的中位數更高量。所以在這樣的前提下,簡短的答案是:整體而言——在你調整其他因素(市場成長、G3,以及其他正在發生的一切)之後——他們的使用量成長速度比其他醫師更快,最高可快到 10%。因此他們回報說,在很短的導入期之後——患者更開心、員工更開心、重複取模更少、因印模被退件而把患者叫回診所的情況更少、矯正器貼合度更好等等、等等、等等,幾乎在每一項指標上都是如此。顯著到對我們很重要,對患者也非常重要。

  • So that's kind a virtuous cycle. It's reinforced and we've had some of those Orthodontists that have maybe several offices go out and buy one for each office and just commit themselves to going completely digital. So, as I said over the last year or so our percentage of fully digital incoming submissions other than PVS has gone up nicely to where now it's about 80%. Then secondly, this is growing very nicely, the all digital for us now of that 80%, a full 6% and climbing nicely are completely digital no-PVS impression and that has lots of benefits for everybody, for us, for the doctor.

    所以這有點像一個良性循環。它會自我強化,而且我們也看到一些矯正專科醫師可能有好幾家診所,於是每家診所都去買一台,並且承諾全面走向數位化。所以,如我所說,過去一年左右,我們收到的完全數位化提交(不含 PVS)比例已經很不錯地提升到現在大約 80%。其次,在這 80% 當中,對我們而言「全數位」也成長得非常好,其中足足有 6% 且持續漂亮攀升的是完全數位、無 PVS 印模,這對所有人都有很多好處,對我們、對醫師都是。

  • An example, two extremes, we have a doctor that puts a case in on Monday and they're getting liners shipped out in states by Thursday or Friday without hustling or expediting a case. In Europe where it might have been four weeks for a full cycle, they're getting aligners back within a couple of weeks and they're getting immediate feedback within a day or two of seeing their ClinCheck. So a lot of positive effects for everybody and the most important thing, it appears the liners fit and therefore, we think ultimately performance will even be better.

    舉個例子,兩個極端:我們有一位醫師在週一提交病例,他們在不需要趕工或加急的情況下,週四或週五就能收到在美國出貨的矯正器。在歐洲,以前完整週期可能要四週,現在他們在兩週左右就能拿到矯正器,而且在看過 ClinCheck 後的一兩天內就能得到即時回饋。所以對每個人都有很多正面效果,而最重要的是,看起來矯正器的貼合度更好,因此我們認為最終的療效甚至會更好。

  • - Analyst

    - Analyst

  • Okay, great. Very helpful and then the last question I'll ask and sorry to go back to sort of the margin/leverage question. But can the 1Q '12 guidance on the top line is somewhat similar with what you put up on the top line for 4Q '11. Yes the non-GAAP op margins are down almost 500 bips q-over-q. So can you just walk us through -- I guess I'm a little perplexed. Gross margin on the non-GAAP comes down 200 basis points but yet I believe you started the Cadent transition actually in the fourth quarter. So, can you maybe walk us through with a little bit more granularity where that 500 bips sequential deleverage is coming from? I know FX has something to do with that. Thanks.

    好的,很棒。非常有幫助。最後一個問題,抱歉又回到毛利/槓桿的問題。但 2012 年第一季的營收指引在某種程度上與你們 2011 年第四季的營收表現相近。然而非 GAAP 的營業利益率卻季對季下降了將近 500 個基點。所以你能帶我們梳理一下——我想我有點困惑。非 GAAP 的毛利率下降了 200 個基點,但我相信你們其實在第四季就開始進行 Cadent 的整合轉換了。所以你能否更細緻地說明一下,這 500 個基點的連續性去槓桿到底是從哪裡來的?我知道匯率(FX)也有影響。謝謝。

  • - VP, CFO

    - VP, CFO

  • Yes. So just to make a point, we started the Cadent business obviously in the April timeframe when we acquired them on April 29, right? So, they were not part of our result. Then when we report out this quarter, we report out Invisalign only for quarter four last year. This year it's obviously a combined business. On a sequential basis, when you look at overall gross margins in the business you have a couple of things going on. The two most significant are, FX which I spoke to, and the other one is we're continuing to expect that doctors will move up in their tierings and attain more rebates from the Advantage Rebate Program based on what we've seen over the past several quarters. Those are probably the two biggest offsetting items to the volume growth that we're seeing in the business from quarter four to quarter one on a sequential basis. Does that make sense?

    是的。先澄清一點,我們是在 4 月收購 Cadent(4 月 29 日)時才開始納入 Cadent 的業務,對吧?所以它們並不包含在我們的業績之中。接著我們在本季對外報告時,去年第四季我們只報告 Invisalign 的業務。而今年顯然是合併後的業務。以季對季來看,當你看整體業務的毛利率時,有幾件事同時在發生。最重要的兩項是:我提到的匯率(FX),以及另一項是我們持續預期醫師會在分級(tierings)上往上移動,並根據過去幾季的觀察,從 Advantage Rebate Program 取得更多回饋(rebates)。這兩項大概是抵銷我們在業務中從第四季到第一季所看到的量成長、在季對季基礎上最主要的兩個因素。這樣說有道理嗎?

  • - President, CEO

    - President, CEO

  • Then operating margin on top of that. Getting it down to the operating margin line.

    那再加上營業利益率。把它一路拉到營業利益率那一行。

  • - VP, CFO

    - VP, CFO

  • Right.

    對。

  • - Analyst

    - Analyst

  • Yes, I understand. I can follow-up offline. I guess what I struggle with is your overall case volume for Invisalign is somewhat similar. 1Q '12 versus 4Q '11, so why would the rebate ratchet up so dramatically q-over-q?

    是的,我了解。我可以線下再追問。我困惑的是,你們 Invisalign 的整體病例量其實差不多。2012 年第一季相較於 2011 年第四季,所以為什麼回饋(rebate)會在季對季之間如此大幅地往上跳?

  • - VP, CFO

    - VP, CFO

  • That has to do with the fact that again, more doctors are participating in the Advantage Rebate Program, attaining the minimums they need, to get a rebate from us. Where a year ago, doctors were starting to make that move in quarter four but as we progressed through 2011 each quarter we're seeing more and more doctors reach the levels to participate in the Rebate Program. Again this quarter, quarter four was a record number of doctors that have achieved that rebate. So again, the number of doctors that achieve rebates when you talk about doing business on a quarterly basis with 12,000 GPs and 4,000 or 5,000 Orthos, again, that entire base is not receiving a rebate. A small percentage of those doctors overall are receiving the rebate but as they're moving up it's having a bit of an impact on ASPs on a quarter-over-quarter basis. Yes, understood. Thanks guys.

    這與一個事實有關:再次強調,越來越多醫師正在參與 Advantage 回饋計畫,達到他們所需的最低門檻,從而可獲得我們提供的回饋。一年前,醫師是在第四季才開始做出這個轉變,但隨著我們在 2011 年逐季推進,我們看到每一季都有越來越多醫師達到參與回饋計畫的門檻。同樣在本季,第四季達成該回饋的醫師人數創下紀錄。因此,再次說明,當你以季度為基礎、與 12,000 名一般牙醫(GP)以及 4,000 或 5,000 名矯正醫師(Ortho)往來時,並不是整個基礎客群都會收到回饋。整體而言,只有一小部分醫師會收到回饋,但隨著他們逐步達到門檻,這在季度對季度的 ASP 上會帶來一些影響。是的,了解。謝謝各位。

  • Operator

    Operator

  • Spencer Nam, ThinkEquity.

    Spencer Nam,ThinkEquity。

  • - Analyst

    - Analyst

  • Just a couple of quick follow-up questions here. Let me start off with the Invisalign Express 5. We've been hearing some speculations that one of your competitors will be coming out with a new tray product that could be pretty competitive. Could this be viewed as your strategic action in anticipation of this launch of a potentially competitive product?

    我這裡有幾個快速的追問。我先從 Invisalign Express 5 開始。我們聽到一些推測,說你們的一位競爭對手將推出一款新的牙套托盤產品,可能相當具有競爭力。這是否可以被視為你們為了因應這項可能具競爭性的產品上市而採取的策略性行動?

  • - President, CEO

    - President, CEO

  • You always make choices around products with a full context of what do customers want and what's growing the market and what's your competitive set doing so I guess at some level, the answer is sure. This was not a tactical response. We've been working on this for a 1.5 years and then doing some testing about the best way to do it. Frankly, with the evolutions in G3 and G4, our view is with our 5-stage product you have got to be able to do more with that product more predictably than anybody else in the world. So if you can get a 5-stage product from anybody why wouldn't you get it from us as long as the price was right. We did a little testing with some different price points and felt that $549 for a 5-stage product with potential refinement and a guarantee on getting to that final position was a pretty compelling offer. So, this was motivated more by ensuring we could be the toughest competitor across the range of aligner-based treatments and then certainly we're still running around in a world of much bigger multi-national companies as competitors and they've got divisions that would love to compete more aggressively with us. So we're always mindful of that and we always kind of stay humble and hungry and make sure we can move faster than them.

    你在產品上做選擇時,總是會在完整脈絡下考量:客戶想要什麼、什麼在推動市場成長,以及競爭對手在做什麼;所以在某個層面上,答案是肯定的。但這並不是一個戰術性的回應。我們已經為此投入了 1.5 年的時間,並進行測試以找出最佳做法。坦白說,隨著 G3 與 G4 的演進,我們的看法是:在我們的 5 階段產品上,你必須能比世界上任何人都更可預測地做到更多。因此,如果你可以從任何人那裡取得 5 階段產品,只要價格合適,為什麼不向我們購買?我們針對不同價位做了一些測試,並認為以 549 美元提供 5 階段產品、包含可能的精修(refinement),以及保證達到最終位置,是相當有吸引力的方案。所以,這更多是出於確保我們能在以隱形矯正器為基礎的治療範圍內成為最強競爭者;而且我們仍然身處一個有更大型跨國公司作為競爭對手的世界,他們旗下也有部門很希望更積極地與我們競爭。因此我們一直保持警覺,也始終保持謙遜與飢渴,確保我們能比他們更快行動。

  • - Analyst

    - Analyst

  • Appreciate that. And then on your guidance, the one question I had. Clearly, you mentioned the factors about the Rebate Program, also the FX effect that's going to impact revenue line, but it seems like there's some level of weakness that -- there's material level of weakness coming from the scanner business that leaves you to guide at where you guided. If you look at the third quarter and fourth quarter of last year, you -- actually the scanner business did more in the third quarter than the fourth quarter. So, should we -- how should we think about the sequential down on scanner business? Should it be off the third-quarter level or off the fourth-quarter level? And it looks like third quarter is actually the strongest quarter rather than the fourth quarter.

    感謝說明。接著關於你們的指引,我有一個問題。很明顯,你們提到了回饋計畫的因素,以及將影響營收的匯率(FX)效應,但看起來似乎還有某種程度的疲弱——掃描器業務出現了相當程度的疲弱,才使你們給出目前這樣的指引。如果你看去年第三季與第四季,你們——其實掃描器業務在第三季的表現比第四季更好。那麼,我們該如何看待掃描器業務的季對季下滑?應該以第三季的水準為基準,還是以第四季的水準為基準?而且看起來第三季其實是最強的一季,而不是第四季。

  • - President, CEO

    - President, CEO

  • So, I know -- Ken's already given some guidance. I'll let that stand. He can comment. I'll just talk in general about the business. We concluded this acquisition at the very end of April and from May on have been working very hard on making choices about the best way to drive value for our customers and our shareholders. And we're still right in the middle of that. There's a lot of moving parts still going on. As Ken said, we just got our sales force built out by the end of Q4 and even with that Q4 was very strong. It was very strong in North America and we expect that trend to continue. We're kind of calling it as we see it. I think we've tried to be very, very clear that we can't, at this point at least, sort out the absolute drivers to softness in Europe. We're going to be able to. We can't yet today. And we're working very hard with our partner to re-stage that growth.

    所以,我知道——Ken 已經給過一些指引了。我就先讓那部分維持不變。他可以再補充。我只就業務整體做一些一般性的說明。我們在四月底才完成這項收購,從五月開始就非常努力地在做出選擇,找出為客戶與股東創造價值的最佳方式。而我們目前仍在這個過程的正中間。仍有許多變動因素在進行中。如 Ken 所說,我們直到第四季末才把銷售團隊建置完成,即便如此,第四季仍然非常強勁。北美表現非常強,我們預期這個趨勢會持續。我們就是依照我們所看到的情況來判斷。我想我們已經非常、非常清楚地說明:至少在目前,我們無法釐清歐洲疲弱的絕對驅動因素。我們會有能力做到。但今天我們還做不到。我們正與合作夥伴非常努力地重新推動那邊的成長。

  • The second thing is we're pretty darn comfortable that we're on the right track in North America, and with sales force together, with a lot of integration of customers and opportunities for leverage in our Invisalign business and those other docs, we're just getting started in the GP side really. So I think there's the good news story. The bad news story is Europe's softer. We're going to figure that out and get after it. But it's no more complicated than that. Capital has a little longer fuse. So we have got reasonable visibility into activity. That's what is going on. Ken, I don't know if you want to pile on.

    第二點是,我們相當有信心北美正走在正確的軌道上;隨著銷售團隊到位,加上在 Invisalign 業務上的大量客戶整合與槓桿機會,以及那些其他醫師資源,我們在一般牙醫(GP)端其實才剛開始真正起步。所以我認為這是好消息的部分。壞消息是歐洲比較疲弱。我們會找出原因並積極處理。但事情並沒有比這更複雜。資本支出(capital)通常有較長的反應時間。因此我們對活動狀況有合理的能見度。目前就是這樣的情況。Ken,我不確定你是否想再補充。

  • - VP, CFO

    - VP, CFO

  • No, I think Tom, you covered it pretty --

    不,我想 Tom 你已經講得很——

  • - Analyst

    - Analyst

  • It sounds like you guys are being -- I don't want to put any words in your mouth, but you guys are being conservative in terms of the outlook and want to make sure that you have something that you guys can work with. Is that fair?

    聽起來你們在展望上採取——我不想替你們說話,但你們在展望上是比較保守的,並希望確保你們提出的是你們能夠掌握並據以執行的內容。這樣說公平嗎?

  • - VP, CFO

    - VP, CFO

  • Spencer, our posture on outlook has not changed. We try to call it as best we can see it. We understand the visibility as well as you do, what we see on the Invisalign side as far as 30 days or so into a quarter. We're getting a little more familiar on the scanner side of the business as we've gotten into it over the past few quarters. But our view of it is we try to put all of the factors together, try to call it as we see it. Make our own assumptions on where we see exchange rates going and volumes in the business going and as Tom just mentioned, the volume in the business in North America is going well for the scanner side of the business. We're having a little bit of an issue. We're working one in Europe as we referred to and the way we look at the Invisalign business is no different than we've always looked at it.

    Spencer,我們對展望的立場沒有改變。我們會盡可能依照我們所能看到的情況來做判斷。我們對能見度的理解和你們一樣,就 Invisalign 端而言,我們能看到大約進入季度後 30 天左右的狀況。至於掃描器業務這一端,隨著過去幾季的深入,我們也更熟悉一些。但我們的看法是:我們會把所有因素綜合起來,並依照我們所看到的情況來做判斷。我們會自行假設匯率走勢與業務量的變化;正如 Tom 剛提到的,北美的掃描器業務量表現良好。我們確實遇到一些問題。如我們所提到的,歐洲那邊我們正在處理;而我們看待 Invisalign 業務的方式,與我們一向的看法並無不同。

  • - Senior Director - Corporate, Investor Communications

    - Senior Director - Corporate, Investor Communications

  • All right. Well, I think we'll conclude it here then. Thank you, operator. Thanks everyone for joining us today. This concludes our conference call. We look forward to seeing you at upcoming financial conferences and industry events. If you have any follow-up questions please contact Investor Relations. Thank you.

    好的。那我想我們就到這裡結束。謝謝接線員。也謝謝各位今天加入我們。本次電話會議到此結束。我們期待在接下來的財務會議與產業活動中與各位見面。如有任何後續問題,請聯絡投資人關係部門。謝謝。

  • Operator

    Operator

  • This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.

    今日電話會議到此結束。您現在可以掛斷電話線。感謝您的參與。